WO2003080046A1 - Azabicyclic, azatricyclic and azaspirocyclic derivatives of aminocyclohexane nmda, 5ht3, and neuronal nicotinic receptor antagoni sts - Google Patents

Azabicyclic, azatricyclic and azaspirocyclic derivatives of aminocyclohexane nmda, 5ht3, and neuronal nicotinic receptor antagoni sts Download PDF

Info

Publication number
WO2003080046A1
WO2003080046A1 PCT/GB2003/001236 GB0301236W WO03080046A1 WO 2003080046 A1 WO2003080046 A1 WO 2003080046A1 GB 0301236 W GB0301236 W GB 0301236W WO 03080046 A1 WO03080046 A1 WO 03080046A1
Authority
WO
WIPO (PCT)
Prior art keywords
hydrochloride
azabicyclo
disease
octane
exo
Prior art date
Application number
PCT/GB2003/001236
Other languages
French (fr)
Inventor
Christopher Graham Raphael Parsons
Markus Henrich
Wojciech Danysz
Ivars Kalvinsh
Valerjans Kauss
Aigars Jirgensons
Markus Gold
Maksims Vanejevs
Original Assignee
Merz Pharma Gmbh & Co. Kgaa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merz Pharma Gmbh & Co. Kgaa filed Critical Merz Pharma Gmbh & Co. Kgaa
Priority to CA002474637A priority Critical patent/CA2474637A1/en
Priority to AU2003216855A priority patent/AU2003216855B2/en
Priority to IL16404103A priority patent/IL164041A0/en
Priority to EA200401230A priority patent/EA007098B1/en
Priority to UA20041008550A priority patent/UA77778C2/en
Priority to JP2003577874A priority patent/JP4262606B2/en
Priority to KR1020047011982A priority patent/KR100741257B1/en
Priority to MXPA04007755A priority patent/MXPA04007755A/en
Priority to EP03712394A priority patent/EP1485086A1/en
Publication of WO2003080046A1 publication Critical patent/WO2003080046A1/en
Priority to NO20044481A priority patent/NO20044481L/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D221/00Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/20Spiro-condensed ring systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D453/00Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/06Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing isoquinuclidine ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02Muscle relaxants, e.g. for tetanus or cramps
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32Alcohol-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34Tobacco-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36Opioid-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/06Antiglaucoma agents or miotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/16Otologicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • A61P33/02Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06Antimalarials
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/54Spiro-condensed
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D221/00Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/22Bridged ring systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D451/00Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08Bridged systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08Bridged systems
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Definitions

  • Azabicyclic, azatricyclic and azaspirocyclic derivatives of aminocyclohexanes which are systemically-active as NMDA, 5HT3, and nicotinic receptor antagonists pharmaceutical compositions comprising the same, method of preparation thereof, and method of treating CNS disorders which involve disturbances of glutamatergic, serotoninergic, and nicotinic transmission therewith, for treating immunomodulatory disorders, and for treating infectious diseases.
  • NMDA N-methyl-D-aspartate
  • Functional inhibition of NMDA receptors can be achieved through actions at different recognition sites such as the primary transmitter site, strychnine-insensitive glycine site (glycine ⁇ ), polyamine site, and phencyclidine site located inside the cation channel.
  • the NMDA receptor channel blockers act in an uncompetitive
  • NMDA receptor antagonists such as amantadine and memantine - which fulfill the above criteria - have been used clinically for several years in the treatment of Parkinson 's disease and dementia respectively, and do indeed rarely produce side effects at the therapeutic doses used in their respective indications.
  • 5-HT3 receptors are ligand gated ionotropic receptors permeable for cations. In man 5-HT3 receptors show the highest density on enterochromaffin cells in the gastrointestinal mucosa, which are innervated by vagal afferents and the area postrema of the brain stem, which forms the chemoreceptor trigger zone.
  • 5-HT3 receptors not only have a high density in the area postrema but also in the hippocampal and amygdala region of the limbic system, it has been suggested that 5-HT3 selective antagonists may have psychotropic effects (Greenshaw & Silverstone, 1997).
  • 5-HT3 receptor antagonists in addition to their well recognized anti-emetic use, may well be clinically useful in a number of areas. These include anxiety disorders, schizophrenia, drug and alcohol abuse disorders, depressive disorders, cognitive disorders, Alzheimer's disease, cerebellar tremor, Parkinson's disease treatment- related psychosis, pain (migraine and irritable bowel syndrome), and appetite disorders.
  • alpha 1 -10) and four beta subunits (beta 1 -4) for nicotinic receptors are known, ⁇ 4 ⁇ 2 receptors are probably the most common in the CNS, especially in the hippocampus and striatum. They form non-selective cation channels with slowly, incompletely desensitizing currents (type II).
  • Homomeric ⁇ 7 receptors are both pre- and postsynaptic and are found in the hippocampus, motor cortex and limbic system as well as in the peripheral autonomic nervous system. These receptors are characterized by their high Ca + permeability and fast, strongly desensitizing responses (type 1A). Changes in nicotinic receptors have been implicated in a number of diseases. These include Alzheimer's disease, Parkinson's disease, Tourette's syndrome, schizophrenia, drug abuse, nicotine abuse, and pain.
  • nicotinic "agonists” may in fact be due to partial agonism, inactivation and/or desensitization of neuronal nicotinic receptors.
  • moderate concentrations of neuronal nicotinic receptor channel blockers could produce the same effects as reported for nicotinic agonists in the above mentioned indications.
  • An additional object of the invention is the provision of a process for producing the azabicyclic, azatricyclic and azaspirocyclic aminocyclohexane active principles.
  • R and R 1 - R 5 are each independently selected from straight or branched chain C ⁇ _6 alkyl groups (e.g. methyl, ethyl, propyl or butyl groups), straight or branched chain C 2 -6 alkenyl groups (e.g. ethenyl or propenyl groups), straight or branched chain C 2 -6 alkynyl groups (e.g. ethynyl or propynyl groups), C ⁇ -12 aryl groups (e.g. phenyl or naphthyl groups), substituted C ⁇ - 12 aryl groups (e.g.
  • C ⁇ _6 alkyl groups e.g. methyl, ethyl, propyl or butyl groups
  • straight or branched chain C 2 -6 alkenyl groups e.g. ethenyl or propenyl groups
  • straight or branched chain C 2 -6 alkynyl groups e.g. ethynyl
  • C ⁇ - ⁇ alkyl such as methyl or ethyl, C1-6 alkoxy such as methoxy or ethoxy, hydroxy and halo such as chloro or bromo), C-6-12 aryl-C ⁇ -4 alkyl groups (e.g. benzyl or phenethyl groups) and, in the case of R and R 2 - R 5 , hydrogen atoms;
  • Z is CH 2 ;
  • N 0 or 1 ;
  • R 2 and R 3 are not hydrogen and at least one of R 4
  • R 5 are not hydrogen
  • alkenylene bridge U-V-W-X, and ring memebers N and Y do not connect to form a
  • the compound is selected for its immunomodulatory, anti-malarial, anti-
  • R is selected from the group consisting of hydrogen, straight or branched chain alkyl (Ci-Ce), straight or branched chain alkenyl (C2-Ce), straight or branched chain
  • alkynyl C ⁇ -Ce
  • aryl substituted aryl
  • arylalkyl
  • R 1 is selected from the group consisting of straight or branched chain alkyl (Ci-C ⁇ ),
  • R 2 through R 5 are independently selected from the group consisting of hydrogen
  • N O or 1 ;
  • alkenylene bridge U-V-W-X, and ring memebers N and Y do not connect to form a
  • an NMDA antagonist selected from the group consisting of
  • excitotoxicity selected from ischaemia during stroke, trauma, hypoxia,
  • hypoglycemia hypoglycemia, glaucoma, and hepatic encephalopathy
  • chronic neurodegenerative diseases selected from Alzheimer's disease, vascular dementia, Parkinson's disease, Huntington's disease, multiple sclerosis,
  • amyotrophic lateral sclerosis amyotrophic lateral sclerosis, AIDS-neurodegeneration, olivopontocerebellar
  • R is selected from the group consisting of hydrogen, straight or branched chain alkyl (Ci-Ce), straight or branched chain alkenyl (C ⁇ -Ce), straight or branched chain
  • alkynyl C2-Ce
  • aryl substituted aryl
  • arylalkyl C2-Ce
  • R 1 is selected from the group consisting of straight or branched chain alkyl (Ci-Ce),
  • R 2 through R 5 are independently selected from the group consisting of hydrogen
  • alkenyl C2-Ce
  • straight or branched chain alkynyl C2-Ce
  • aryl substituted aryl
  • N 0 or 1 ;
  • alkenylene bridge U-V-W-X, and ring memebers N and Y do not connect to form a
  • the living animal an amount of a compound selected from those of formula 1 ,
  • R is selected from the group consisting of hydrogen, straight or branched chain
  • alkyl (Ci-Ce), straight or branched chain alkenyl (C ⁇ -Ce), straight or branched chain
  • alkynyl C ⁇ -Ce
  • aryl substituted aryl
  • arylalkyl
  • R 1 is selected from the group consisting of straight or branched chain alkyl (Ci-Ce),
  • R 2 through R 5 are independently selected from the group consisting of hydrogen
  • N 0 or 1 ;
  • alkenylene bridge U-V-W-X, and ring memebers N and Y do not connect to form a
  • R is selected from the group consisting of hydrogen, straight or branched chain
  • alkyl (Ci-Ce), straight or branched chain alkenyl (C2-Ce), straight or branched chain
  • alkynyl C ⁇ -Ce
  • aryl substituted aryl
  • arylalkyl
  • R 1 is selected from the group consisting of straight or branched chain alkyl (Ci-Ce),
  • R 2 through R 5 are independently selected from the group consisting of hydrogen, straight or branched chain alkyl (Ci-Ce), straight or branched chain alkenyl (C2-C6),
  • N O or 1 ;
  • alkenylene bridge U-V-W-X, and ring memebers N and Y do not connect to form a
  • Parkinson's disease cerebellar tremor, migraine, appetite disorders,
  • IBS inflammatory bowel syndrome
  • emesis inflammatory bowel syndrome
  • R is selected from the group consisting of hydrogen, straight or branched chain
  • alkyl (Ci-Ce), straight or branched chain alkenyl (C ⁇ -Ce), straight or branched chain
  • alkynyl C2-Ce
  • aryl substituted aryl
  • arylalkyl C2-Ce
  • R 1 is selected from the group consisting of straight or branched chain alkyl (Ci-C ⁇ ),
  • R 2 through R 5 are independently selected from the group consisting of hydrogen
  • N 0 or 1 ;
  • alkenylene bridge U-V-W-X, and ring memebers N and Y do not connect to form a
  • neuronal nicotinic receptor antagonist selected from the group
  • Tourette's syndrome anxiety disorders
  • Schizophrenia drug
  • ADHD attention deficit hyperactivity disorder
  • Parkinson's disease, and pain comprising the step of administering to the living
  • R is selected from the group consisting of hydrogen, straight or branched chain
  • alkyl (Ci-Ce), straight or branched chain alkenyl (C2-Ce), straight or branched chain
  • alkynyl C2-Ce
  • aryl substituted aryl
  • arylalkyl C2-Ce
  • R 1 is selected from the group consisting of straight or branched chain alkyl (Ci-Ce),
  • R 2 through R 5 are independently selected from the group consisting of hydrogen,
  • N 0 or 1 ;
  • alkenylene bridge U-V-W-X, and ring memebers N and Y do not connect to form a
  • Such a pharmaceutical composition consisting of a compound selected from
  • R is selected from the group consisting of hydrogen, straight or branched chain
  • alkyl (Ci-Ce), straight or branched chain alkenyl (d-C ⁇ ), straight or branched chain
  • R 1 is selected from the group consisting of straight or branched chain alkyl (Ci-Ce),
  • R 2 through R 5 are independently selected from the group consisting of hydrogen
  • N 0 or 1 ;
  • alkenylene bridge U-V-W-X, and ring memebers N and Y do not connect to form a
  • Example 3b A colorless oil.
  • hydrochloride 1-5 (0.25 g, 26%) as a colorless solid.
  • Example 3b A colorless oil.
  • Example 3c A colorless solid.
  • Cyclohexanone 13 (4.0 g, 53%) was obtained as a colorless oil.
  • lactam 18 (0.07 g, 0.385 mmol) in tetrahydrofuran (2 ml) and refluxed for 15 h.
  • Example 9a A colorless crystals with mp 130-131 °C.
  • Example 9b An oil.
  • Example 9c A colorless solid with mp 1 58-160 °C.
  • Example 10a A colorless oil.
  • Example 9a Colorless solid with mp 140-141 °C.
  • Example 9b A colorless oil.
  • Example 9c Colorless solid with mp 126-128° C. 'H-NMR (CDCb, TMS) ⁇ : 1 .01 (6H, s, 8,10- CHs); 1 .09 (6H, s, 8, 10-CHs); 1.19 and
  • Example 9d A colorless solid.
  • Example 3b An oil.
  • the active ingredients of the invention may be placed into the form of pharmaceutical compositions and unit dosages thereof, and in such form may be employed as solids, such as coated or uncoated tablets or filled capsules, or liquids, such as solutions, suspensions, emulsions, elixirs, or capsules filled with the same, all for oral use; in the form of suppositories or capsules for rectal administration or in the form of sterile injectable solutions for parenteral (including intravenous or subcutaneous) use.
  • Such pharmaceutical compositions and unit dosage forms thereof may comprise conventional or new ingredients in conventional or special proportions, with or without additional active compounds or principles, and such unit dosage forms may contain any suitable effective amount of the active ingredient commensurate with the intended daily dosage range to be employed.
  • the active principles of the invention may be administered to a subject, e.g., a living animal (including a human) body, in need thereof, for the treatment, alleviation, or amelioration, palliation, or elimination of an indication or condition which is susceptible thereto, or representatively of an indication or condition set forth elsewhere in this application, preferably concurrently, simultaneously, or together with one or more pharmaceutically-acceptable excipients, carriers, or diluents, especially and preferably in the form of a pharmaceutical composition thereof, whether by oral, rectal, or parental (including intravenous and subcutaneous) or in some cases even topical route, in an effective amount.
  • Suitable dosage ranges are 1-1000 milligrams daily, preferably 10-500 milligrams daily, and especially 50-500 milligrams daily, depending as usual upon the exact mode of administration, form in which administered, the indication toward which the administration is directed, the subject involved and the body weight of the subject involved, and the preference and experience of the physician or veterinarian in charge.
  • reaction products can be processed into tablets, coated tablets, capsules, drip solutions, suppositories, injection and infusion preparations, and the like and can be therapeutically applied by the oral, rectal, parenteral, and additional routes.
  • Representative pharmaceutical compositions follow.
  • Tablets suitable for oral administration which contain the active ingredient may be prepared by conventional tabletting techniques.
  • any usual suppository base may be employed for incorporation thereinto by usual procedure of the active ingredient, such as a polyethyleneglycol which is a solid at normal room temperature but which melts at or about body temperature.
  • a suitable formulation for a tablet containing 10 milligrams of active ingredient is as follows:
  • EXAMPLE 2 Tablet Formulation Another suitable formulation for a tablet containing 100 mg is as follows:
  • Polyvinylpyrrolidone 10 Film coated and colored.
  • the film coating material consists of:
  • a suitable formulation for a capsule containing 50 milligrams of active ingredient is as follows:
  • a suitable formulation for an injectable solution containing one percent of active ingredient is as follows:
  • a suitable formulation for 1 liter of a liquid mixture containing 2 milligrams of active ingredient in one milliliter of the mixture is as follows:
  • Another suitable formulation for 1 liter of a liquid mixture containing 20 milligrams of active ingredient in one milliliter of the mixture is as follows:
  • Sweet orange peel tincture 15 Purified water to make a total of 1000 ml.
  • Aerosol formulation 180 g aerosol solution contain:
  • Polybutylcyanoacrylate nanoparticles are prepared by emulsion polymerization in a water/0.1 N HCI/ethanol mixture as polymerizsation medium. The nanoparticles in the suspension are finally lyophilized under vacuum.
  • NMDA receptor antagonists are systemically-active, uncompetitive NMDA receptor antagonists with rapid blocking/unblocking kinetics and strong voltage dependency and are, accordingly, of utility in the treatment, elimination, palliation, alleviation, and amelioration of responsive conditions, by application or administration to the living animal host for the treatment of a wide range of CNS disorders which involve disturbances of glutamatergic transmission.
  • These compounds are also systemically-active, non-competitive 5HT3 and neuronal nicotinic receptor antagonists and are, accordingly, of utility in the treatment, elimination, palliation, alleviation, and amelioration of responsive conditions, by application or administration to the living animal host for the treatment of a wide range of CNS disorders which involve disturbances of serotonin or nicotinic transmission.
  • the pellet was then re- suspended and centrifuged two to three more times at 48,000xg for 20 min in the presence of 50 mM Tris-HCI, pH 8.0. All centrifugation steps were carried out at 4°C. After resuspension in 5 volumes of 50 mM Tris-HCI, pH 8.0 the membrane suspension was frozen rapidly at -80°C.
  • OR-2 100 mM NaCI, 2 mM KCI, 1 mM MgCb, 2 mM
  • RNA for the NR2A subunit was mixed 1 : 1 with RNA for the NR2A subunit.
  • nicotinic ⁇ 4 RNA was mixed 1 :1 with RNA for the ⁇ 2 subunit. Fifty to 100
  • nanoliters of each RNA mixture were injected in the oocyte's cytoplasm using a
  • the electrodes had a resistance between 0.2 and 0.4 M ⁇ and were
  • the bath solution was prepared Ca 2+ -free, to avoid
  • NMDA receptors were activated by the manual co-application of 1
  • Neuronal nicotinic receptors were activated by application of
  • Hippocampi were obtained from rat embryos (E20 to E21 ) and were then transferred to calcium and magnesium free Hank's buffered salt solution (Gibco) on ice. Cells were mechanically dissociated in 0.05% DNAase / 0.3% ovomucoid (Sigma) following an 8 minute pre-incubation with 0.66% trypsin /
  • Patch clamp recordings were made from these neurones with polished glass electrodes (4-6 m) in the whole cell mode at room temperature (20-22C) with the aid of an EPC-7 amplifier (List).
  • Test substances were applied by switching channels of a custom-made fast superfusion system with a common outflow (10-20 ms exchange times).
  • the contents of the intracellular solution were as follows (mM): CsCI (120), TEACI (20), EGTA (10), MgCb(1 ),CaCl2(0.2), glucose (10), ATP(2), cAMP (0.25); pH was adjusted to 7.3 with CsOH or HCI.
  • the extracellular solutions had the following basic composition (mM): NaCI (140), KCI (3), CaC (0.2), glucose (10), HEPES (10), sucrose (4.5), tetrodotoxin (TTX 3* 10 "4 ).
  • Glycine (1 M) was present in all solutions: a concentration sufficient to cause around 80-85% activation of glycine ⁇ receptors. Only results from stable cells were accepted for inclusion in the final analysis, i.e., following recovery of responses to NMDA by at least 75% of their depression by the antagonists tested.
  • N1 E-1 15 cells were purchased from the European collection of cell cultures (ECACC, Salisbury, UK) and stored at -80°C until further use. The cells were plated at a density of 100,000 cells cm "2 onto plastic Petri dishes (Falcon) and were nourished with NaHCOs/HEPES-buffered minimum essential medium supplemented (MEM) with 15% fetal calf serum (Gibco) and incubated at 37°C with 5%CO2 at 95% humidity. The medium was exchanged completely daily. Once every three days, cells were reseeded onto fresh Petri dishes following treatment with trypsin-EDTA (1 % in PBS), resuspension in MEM and centrifugation at 1000 rpm for four minutes.
  • MEM NaHCOs/HEPES-buffered minimum essential medium supplemented
  • Gibco fetal calf serum
  • Patch clamp recordings at -70 mV were made from lifted cells, 2-3 days following seeding with polished glass electrodes (2-6M ⁇ ) in the whole cell mode at room temperature (20-22°C) with an EPC-7 amplifier (List).
  • the contents of the intracelluiar solution were as follows (mM): CsCI(130), HEPES (10), EGTA (10), MgCb (2), CaCb (2), K-ATP (2), Tris-GTP (0.2), D-glucose (10); pH was adjusted to 7.3 with CsOH or HCI.
  • the extracellular solutions had the following basic composition (mM): NaCI (124), KCI (2.8), HEPES (10), pH 7.3 adjusted with NaOH or HCI.
  • the cells were lifted from the glass substrate and serotonin (10 ⁇ M), memantine and unsaturated amino- alkyl-cyclohexane derivatives were applied at various concentrations using a fast superfusion device.
  • a piezo translator-driven double-barrelled application pipette was used to expose the lifted cell either to serotonin-free or serotonin-containing solution.
  • a two second serotonin pulse was delivered every 6O seconds.
  • the putative antagonists were dissolved in aqua-bidest and diluted with bath solution to the desired concentration. Only results from stable cells were accepted for inclusion in the final analysis, i.e., showing at least 50% recovery of responses to serotonin following removal of compounds.
  • NMR female mice (18-28 g) housed 5 per cage were used for the maximal electroshock (MES) and motor impairment tests. All animals were kept with water and food ad libitum under a 12 hour light-dark cycle (light on at 6 a.m.) and at a controlled temperature (20 + 0.5C). All experiments were performed between 10 a.m. and 5 p.m. Tested agents were injected 30 min. i.p. before the induction of convulsions if not stated otherwise (see below). All compounds were dissolved in 0.9% saline.
  • MES electroshock
  • the MES test was performed together with tests for myorelaxant action (traction reflex) and motor coordination (rotarod).
  • traction reflex mice were placed with their forepaws on a horizontal rod and were required to place all 4 paws on the wire within 10 seconds.
  • ataxia mice were placed on an accelerating rotarod and were required to remain on the rod for 1 minute. Only mice not achieving the criteria in all three repetitions of each test were considered to exhibit myorelaxation or ataxia respectively.
  • MES 100 Hz, 0.5 second shock duration, 50 mA shock intensity, 0.9 ms impulse duration, Ugo Basile
  • tonic convulsions The presence of tonic convulsions was scored (tonic extension of hind paws with minimum angle to the body of 90). The aim was to obtain ED50S for all parameters scored (anticonvulsive activity and motor side effects) with use of the Litchfield Wilcoxon test for quantal dose responses. Division of the ED50 for side, effects (ataxia or myorelaxation) by the ED50 for antagonism of electroshock convulsions was used as a therapeutic index (TI).
  • IC50S in patch clamp and binding studies were calculated according to the four parameter logistic equation using the Grafit computer program (Erithacus Software, England). Ki value for binding studies were then determined according to Cheng and Prusoff. Binding values presented are means ⁇ SEM of 3-5 determinations (each performed in duplicate).
  • MRZ numbers are used to represent chemical names.
  • the MRZ numbers and their respective chemical names are shown in "MRZ LIST", and are cross- referenced in the Examples
  • NMDA receptor blockade by MRZ 2/1010 was determined by applying various concentrations (0.3 to 30 ⁇ M in a log 3 dosing regime) for 10 seconds in the continuous presence of glutamate (100 ⁇ M) and glycine 10 ⁇ M) at -70 mV for 100 seconds in Xenopus oocytes expressing NR1 a/2A receptors ( Figure 2, left).
  • the present invention provides novel, valuable, and unpredictable applications and uses of the compounds of the present invention, which compounds comprise the active principle according to the present invention, as well as novel pharmaceutical compositions thereof and methods of preparation thereof and of treating therewith, all possessed of the foregoing more specifically-enumerated characteristics and advantages.
  • the instant azabicyclic, azatricyclic and azaspirocyclic derivatives of aminocyclohexanes represent a novel class of systemically-active, uncompetitive NMDA receptor antagonists with rapid blocking/unblocking kinetics and strong voltage-dependency. In view of their moderate potency and associated rapid kinetics, they will be useful therapeutics in a wide range of CNS disorders which involve disturbances of glutamatergic transmission.
  • Excitotoxicity such as ischaemia during stroke, trauma, hypoxia, hypoglycemia, glaucoma, and hepatic
  • these compounds are neuronal nicotinic receptor and 5HT3 receptor antagonists as well.
  • the compounds of the invention thus find application in the treatment of disorders in a living animal body, especially a human, in both nicotinic and 5HT3 receptor mediated indications for both symptomatic and neuroprotective purposes (e.g. emesis, nicotine abuse, schizophrenia, cerebellar tremor, IBS, migraine, depressive disorders, cognitive disorders, Parkinson's disease treatment-related psychosis and appetite disorders).
  • the compounds of the present invention are also effective in indications not related to the aforementioned mechanism of action, exhibiting immunomodulatory activity, antimalaria and antitrypanozomal potency, anti- Borna virus, anti-HSV and anti-Hepatitis C virus activity.
  • the method-of-treating a living animal body with a compound of the invention, for the inhibition of progression or alleviation of the selected ailment therein, is as previously stated by any normally-accepted pharmaceutical route, employing the selected dosage which is effective in the alleviation of the particular ailment desired to be alleviated.
  • Use of the compounds of the present invention in the manufacture of a medicament for the treatment of a living animal for inhibition of progression or alleviation of selected ailments or conditions, particularly ailments or conditions susceptible to treatment with an NMDA receptor antagonist, neuronal nicotinic receptor antagonist, 5HT3 antagonist, or a compound exhibiting immunomodulatory activity, antimalaria and antitrypanosomal potency, anti- Borna virus, and anti-HSV and anti-Hepatitis C virus activity, is carried out in the usual manner comprising the step of admixing an effective amount of a compound of the invention with a pharmaceutically-acceptable diluent, excipient, or carrier, and the method-of-treating, pharmaceutical compositions, and use of a compound of the present invention in the manufacture of a medicament.
  • compositions prepared by admixing the active ingredient with a suitable pharmaceutically-acceptable excipient, diluent, or carrier include tablets, capsules, solutions for injection, liquid oral formulations, aerosol formulations, TDS formulations, and nanoparticle formulations, thus to produce medicaments for oral, injectable, or dermal use, also in accord with the foregoing.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychology (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Hospice & Palliative Care (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Otolaryngology (AREA)
  • AIDS & HIV (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Azabicyclic, azatricyclic and azaspirocyclic derivatives of aminocyclohexanes of formula I (N, Y, Z,, R, R1-R5 as defined in the claims) which are systemically-active as NMDA, 5HT3, and nicotinic receptor antagonists, pharmaceutical compositions comprising the same, method of preparation thereof, and method of treating CNS disorders which involve disturbances of glutamatergic, serotoninergic, and nicotinic transmission, treating immunomodulatory disorders, and antimalaria, antitrypanosomal, anti-Borna virus, anti-HSV and anti-Hepatitis C virus activity.

Description

AZABICYCLIC , AZATRICYCLIC AND AZASPIROCYCLIC DERIVATIVES OF AMINOCYCLOHEXANE AS NMDA, 5HT3 , AND NEURONAL NICOTINIC RECEPTOR ANTAGONISTS
1. Field of the Invention
Azabicyclic, azatricyclic and azaspirocyclic derivatives of aminocyclohexanes which are systemically-active as NMDA, 5HT3, and nicotinic receptor antagonists, pharmaceutical compositions comprising the same, method of preparation thereof, and method of treating CNS disorders which involve disturbances of glutamatergic, serotoninergic, and nicotinic transmission therewith, for treating immunomodulatory disorders, and for treating infectious diseases.
2. Prior Art NMDA Antagonists
Antagonism of glutamate receptors of the N-methyl-D-aspartate (NMDA) type has a potentially wide range of therapeutic applications [19]. Functional inhibition of NMDA receptors can be achieved through actions at different recognition sites such as the primary transmitter site, strychnine-insensitive glycine site (glycineβ), polyamine site, and phencyclidine site located inside the cation channel. The NMDA receptor channel blockers act in an uncompetitive
"use-dependent" manner, meaning that they usually only block the channel in the open state. This use-dependence has been interpreted by many to mean that stronger activation of the receptor should lead to a greater degree of antagonism. Such a mode of action has further been taken to imply that this class of antagonist may be particularly useful when overactivation of NMDA receptors can be expected, such as in epilepsy, ischaemia, and trauma. However, initial clinical experience with the selective, high affinity, strongly use- dependent uncompetitive NMDA receptor antagonist ( + )-5-methyl-10,1 1- dihydro-5H-dibenzocyclohepten-5,10-imine maleate {( + )-MK-801 ) has been disappointing. Namely, therapeutic efficacy in epilepsy was poor while some psychotropic side effects were apparent at therapeutic doses. These observations, together with the fact that phencyclidine abusers experience similar psychotropic symptoms, has led to the conclusion that uncompetitive antagonism of NMDA receptors may not be a promising therapeutic approach.
However, the use of more elaborate electrophysiological methods indicates that there is no equality between different uncompetitive antagonists since factors such as the speed of receptor blockade (on-off kinetics) and the voltage-dependence of this effect may determine the pharmacodynamic features in vivo, i.e., therapeutic safety as well. Paradoxically, agents with low to moderate, rather than high, affinity may be desirable. Such findings triggered a reconsideration of the concept of uncompetitive antagonism of NMDA receptors in drug development [19, 22]. Uncompetitive NMDA receptor antagonists, such as amantadine and memantine - which fulfill the above criteria - have been used clinically for several years in the treatment of Parkinson 's disease and dementia respectively, and do indeed rarely produce side effects at the therapeutic doses used in their respective indications.
In view of the above mentioned evidence, we have developed a series of novel uncompetitive NMDA receptor antagonists based on the azabicyclic, azatricyclic and azaspirocyclic aminocyclohexane structure. 5-HT3 Receptor Antagonists
5-HT3 receptors are ligand gated ionotropic receptors permeable for cations. In man 5-HT3 receptors show the highest density on enterochromaffin cells in the gastrointestinal mucosa, which are innervated by vagal afferents and the area postrema of the brain stem, which forms the chemoreceptor trigger zone.
Since 5-HT3 receptors not only have a high density in the area postrema but also in the hippocampal and amygdala region of the limbic system, it has been suggested that 5-HT3 selective antagonists may have psychotropic effects (Greenshaw & Silverstone, 1997).
Indeed, early animal studies suggested that the 5-HT3 receptor antagonists, in addition to their well recognized anti-emetic use, may well be clinically useful in a number of areas. These include anxiety disorders, schizophrenia, drug and alcohol abuse disorders, depressive disorders, cognitive disorders, Alzheimer's disease, cerebellar tremor, Parkinson's disease treatment- related psychosis, pain (migraine and irritable bowel syndrome), and appetite disorders.
Neuronal nicotinic receptor antagonists
At present, ten alpha subunits (alpha 1 -10) and four beta subunits (beta 1 -4) for nicotinic receptors are known, α4β2 receptors are probably the most common in the CNS, especially in the hippocampus and striatum. They form non-selective cation channels with slowly, incompletely desensitizing currents (type II). Homomeric α7 receptors are both pre- and postsynaptic and are found in the hippocampus, motor cortex and limbic system as well as in the peripheral autonomic nervous system. These receptors are characterized by their high Ca + permeability and fast, strongly desensitizing responses (type 1A). Changes in nicotinic receptors have been implicated in a number of diseases. These include Alzheimer's disease, Parkinson's disease, Tourette's syndrome, schizophrenia, drug abuse, nicotine abuse, and pain.
Based on the observation that the nicotinic agonist nicotine itself seems to have beneficial effects, drug development so far is aimed at the discovery of selective nicotinic agonists.
On the other hand, it is unclear whether the effects of nicotinic agonists in, e.g., Tourette's syndrome and schizophrenia, are due to activation or inactivation / desensitization of neuronal nicotinic receptors.
The effects of agonists on neuronal nicotinic receptors is strongly ' dependent on the exposure period. Rapid reversible desensitization occurs in milliseconds, rundown occurs in seconds, irreversible inactivation of α4β2 and α7 containing receptors occurs in hours and their upregulation occurs within days.
In other words, the effects of nicotinic "agonists" may in fact be due to partial agonism, inactivation and/or desensitization of neuronal nicotinic receptors. In turn, moderate concentrations of neuronal nicotinic receptor channel blockers could produce the same effects as reported for nicotinic agonists in the above mentioned indications.
THE PRESENT INVENTION
It has now been found that certain azabicyclic, azatricyclic and azaspirocyclic derivatives of aminocyclohexanes have pronounced and unpredictable NMDA, 5HT3, and nicotinic receptor antagonistic activity. Owing to the aforementioned property, the substances are suited for the treatment of a wide range of CNS disorders which involve disturbances of glutamatergic, serotoninergic, and nicotinic transmission, immunomodulatory effect, and anti- infectious diseases properties. These compounds are preferably in the form of a pharmaceutical composition thereof wherein they are present together with one or more pharmaceutically-acceptable diluents, carriers, or excipients. OBJECTS OF THE INVENTION
It is an object of the present invention to provide novel pharmaceutical compounds which are azabicyclic, azatricyclic and azaspirocyclic aminocyclohexane NMDA, 5HT3, and nicotinic receptor antagonists and pharmaceutical compositions thereof. It is a further object of the invention to provide a novel method of treating, eliminating, alleviating, palliating, or ameliorating undesirable CNS disorders which involve disturbances of glutamatergic, serotoninergic, nicotinic transmission, for treating immunomodulatory disorders, and for treating infectious diseases by employing a compound of the invention or a pharmaceutical composition containing the same. An additional object of the invention is the provision of a process for producing the azabicyclic, azatricyclic and azaspirocyclic aminocyclohexane active principles. Yet additional objects will become apparent hereinafter, and still further objects will be apparent to one skilled in the art.
SUMMARY OF THE INVENTION
What we therefore believe to be comprised by our invention may be summarized inter alia in the following words:
A compound selected from those of formula 1,
Figure imgf000008_0001
1
wherein
R and R1 - R5 are each independently selected from straight or branched chain Cι_6 alkyl groups (e.g. methyl, ethyl, propyl or butyl groups), straight or branched chain C2-6 alkenyl groups (e.g. ethenyl or propenyl groups), straight or branched chain C2-6 alkynyl groups (e.g. ethynyl or propynyl groups), Cε-12 aryl groups (e.g. phenyl or naphthyl groups), substituted Cε-12 aryl groups (e.g. carrying one or more substituents selected from Cι-β alkyl such as methyl or ethyl, C1-6 alkoxy such as methoxy or ethoxy, hydroxy and halo such as chloro or bromo), C-6-12 aryl-Cι-4 alkyl groups (e.g. benzyl or phenethyl groups) and, in the case of R and R2 - R5, hydrogen atoms;
Z is CH2;
N = 0 or 1 ;
Y = CH;
and provided that at least one of R2 and R3 are not hydrogen and at least one of R4
and R5 are not hydrogen;
or those compounds wherein R and R1 combine to form a C3-C5 alkylene or
alkenylene bridge U-V-W-X, resulting in the structure represented by formula 2,
Figure imgf000009_0001
wherein X = CH2;
m = 0, 1 , 2;
or those compounds wherein R and R1 combine to form a C3-C5 alkylene or
alkenylene bridge U-V-W-X, and ring memebers N and Y do not connect to form a
bridge, resulting in the basic structure represented by formula 3
Figure imgf000009_0002
wherein ring member N is saturated and ring member Y is saturated or may
combine together with R5 to form a carbon-hydrogen bond with the ring carbon to
which it is attached;
its optical isomers and pharmaceutically-acceptable acid or base addition salt
thereof;
such a method-of-treating a living animal for alleviation of a condition
wherein the compound is selected for its immunomodulatory, anti-malarial, anti-
Borna virus, or anti-Hepatitis C, anti-trypanosomal, and anti-HSV efficacy,
comprising the step of administering to the living animal an amount of a
compound selected from those of formula 1 ,
Figure imgf000010_0001
wherein
R is selected from the group consisting of hydrogen, straight or branched chain alkyl (Ci-Ce), straight or branched chain alkenyl (C2-Ce), straight or branched chain
alkynyl (C∑-Ce), aryl, substituted aryl, and arylalkyl;
R1 is selected from the group consisting of straight or branched chain alkyl (Ci-Cε),
straight or branched chain alkenyl (C2-Ce), straight or branched chain alkynyl (C2-
Ce), aryl, substituted aryl, and arylalkyl;
R2 through R5 are independently selected from the group consisting of hydrogen,
straight or branched chain alkyl (Ci-Ce), straight or branched chain alkenyl (C2-Ce),
straight or branched chain alkynyl (C2-C6), aryl, substituted aryl, and arylalkyl;
N = O or 1 ;
Y = CH;
or those compounds wherein R and R1 combine to form a C3-C5 alkylene or
alkenylene bridge U-V-W-X, resulting in the structure represented by formula 2,
Figure imgf000011_0001
wherein X = CH2,- m = 0, 1 , 2;
or those compounds wherein R and R1 combine to form a C3-C5 alkylene or
alkenylene bridge U-V-W-X, and ring memebers N and Y do not connect to form a
bridge, resulting in the basic structure represented by formula 3,
Figure imgf000012_0001
wherein ring member N is saturated and ring member Y is saturated or may
combine together with R5 to form a carbon-hydrogen bond with the ring carbon to
which it is attached;
its optical isomers and pharmaceutically-acceptable acid or base addition salt
thereof;
which is effective for alleviation of said condition;
such a method-of-treating a living animal for alleviation of a condition
treatable by an NMDA antagonist selected from the group consisting of
excitotoxicity selected from ischaemia during stroke, trauma, hypoxia,
hypoglycemia, glaucoma, and hepatic encephalopathy,
chronic neurodegenerative diseases selected from Alzheimer's disease, vascular dementia, Parkinson's disease, Huntington's disease, multiple sclerosis,
amyotrophic lateral sclerosis, AIDS-neurodegeneration, olivopontocerebellar
atrophy, Tourette's syndrome, motor neurone disease, mitochondrial
dysfunction, Korsakoff syndrome, and Creutzfeldt-Jakob disease,
other disorders related to long term plastic changes in the central nervous
system selected from chronic pain, drug tolerance, dependence and addiction
(e.g., opioids, cocaine, benzodiazepines, nicotine, and alcohol), and
epilepsy, tardive dyskinesia, L-DOPA-induced dyskinesia, schizophrenia,
anxiety, depression, acute pain, spasticity, and tinnitus,
comprising the step of administering to the living animal an amount of a
compound selected from those of formula 1 ,
Figure imgf000013_0001
1
wherein
R is selected from the group consisting of hydrogen, straight or branched chain alkyl (Ci-Ce), straight or branched chain alkenyl (C∑-Ce), straight or branched chain
alkynyl (C2-Ce), aryl, substituted aryl, and arylalkyl;
R1 is selected from the group consisting of straight or branched chain alkyl (Ci-Ce),
straight or branched chain alkenyl (C2-C6), straight or branched chain alkynyl (C2-
Ce), aryl, substituted aryl, and arylalkyl;
R2 through R5 are independently selected from the group consisting of hydrogen,
straight or branched chain alkyl (Ci-Ce), straight or branched chain
alkenyl (C2-Ce), straight or branched chain alkynyl (C2-Ce), aryl, substituted aryl, and
arylalkyl;
N =0 or 1 ;
Y = CH;
or those compounds wherein R and R1 combine to form a C3-C5 alkylene or
alkenylene bridge U-V-W-X, resulting in the structure represented by formula 2,
Figure imgf000014_0001
wherein X = CH2,-
m = 0, 1 , 2;
or those compounds wherein R and R1 combine to form a C3-C5 alkylene or
alkenylene bridge U-V-W-X, and ring memebers N and Y do not connect to form a
bridge, resulting in the basic structure represented by formula 3,
Figure imgf000015_0001
wherein ring member N is saturated and ring member Y is saturated or may
combine together with R5 to form a carbon-hydrogen bond with the ring carbon to
which it is attached;
its optical isomers and pharmaceutically-acceptable acid or base addition salt
thereof;
which is effective for alleviation of said condition;
such a method-of-treating a living animal for alleviation of a condition
treatable by a 5HT3 receptor antagonist, comprising the step of administering to
the living animal an amount of a compound selected from those of formula 1 ,
Figure imgf000016_0001
1
wherein
R is selected from the group consisting of hydrogen, straight or branched chain
alkyl (Ci-Ce), straight or branched chain alkenyl (C∑-Ce), straight or branched chain
alkynyl (C∑-Ce), aryl, substituted aryl, and arylalkyl;
R1 is selected from the group consisting of straight or branched chain alkyl (Ci-Ce),
straight or branched chain alkenyl (C2-C6), straight or branched chain alkynyl (C2-
Ce), aryl, substituted aryl, and arylalkyl;
R2 through R5 are independently selected from the group consisting of hydrogen,
straight or branched chain alkyl (Ci-Cβ), straight or branched chain alkenyl (C2-Ce),
straight or branched chain alkynyl (C2-Ce), aryl, substituted aryl, and arylalkyl;
N = 0 or 1 ;
Y = CH;
or those compounds wherein R and R1 combine to form a C3-C5 alkylene or alkenylene bridge U-V-W-X, resulting in the structure represented by formula 2,
Figure imgf000017_0001
wherein X = CH2;
m = 0, 1 , 2;
or those compounds wherein R and R1 combine to form a C3-C5 alkylene or
alkenylene bridge U-V-W-X, and ring memebers N and Y do not connect to form a
bridge, resulting in the basic structure represented by formula 3,
Figure imgf000017_0002
wherein ring member N is saturated and ring member Y is saturated or may
combine together with R5 to form a carbon-hydrogen bond with the ring carbon to
which it is attached;
its optical isomers and pharmaceutically-acceptable acid or base addition salt
thereof; which is effective for alleviation of said condition;
such a method-of-treating a living animal for alleviation of a condition
treatable by a neuronal nicotinic receptor antagonist, comprising the step of
administering to the living animal an amount of a compound selected from those
of formula 1 ,
Figure imgf000018_0001
1
wherein
R is selected from the group consisting of hydrogen, straight or branched chain
alkyl (Ci-Ce), straight or branched chain alkenyl (C2-Ce), straight or branched chain
alkynyl (C∑-Ce), aryl, substituted aryl, and arylalkyl;
R1 is selected from the group consisting of straight or branched chain alkyl (Ci-Ce),
straight or branched chain alkenyl (C2-C6), straight or branched chain alkynyl (C2-
Ce), aryl, substituted aryl, and arylalkyl;
R2 through R5 are independently selected from the group consisting of hydrogen, straight or branched chain alkyl (Ci-Ce), straight or branched chain alkenyl (C2-C6),
straight or branched chain alkynyl (C2-C6), aryl, substituted aryl, and arylalkyl;
N =O or 1 ;
Y = CH;
or those compounds wherein R and R1 combine to form a C3-C5 alkylene or
alkenylene bridge U-V-W-X, resulting in the structure represented by formula 2,
Figure imgf000019_0001
wherein X = CH2,"
m = 0, 1 , 2;
or those compounds wherein R and R1 combine to form a C3-C5 alkylene or
alkenylene bridge U-V-W-X, and ring memebers N and Y do not connect to form a
bridge, resulting in the basic structure represented by formula 3,
Figure imgf000020_0001
wherein ring member N is saturated and ring member Y is saturated or may
combine together with R5 to form a carbon-hydrogen bond with the ring carbon to
which it is attached;
its optical isomers and pharmaceutically-acceptable acid or base addition salt
thereof;
which is effective for alleviation of said condition;
such a method-of-treating a living animal for alleviation of a condition
treatable by a 5HT3 antagonist selected from the group consisting of anxiety
disorders, depressive disorders, Schizophrenia and treatment related psychosis,
drug and alcohol abuse disorders, cognitive disorders, Alzheimer's disease,
Parkinson's disease, cerebellar tremor, migraine, appetite disorders,
inflammatory bowel syndrome (IBS), and emesis, comprising the step of
administering to the living animal an amount of a compound selected from
those of formula 1 ,
Figure imgf000021_0001
1
wherein
R is selected from the group consisting of hydrogen, straight or branched chain
alkyl (Ci-Ce), straight or branched chain alkenyl (C∑-Ce), straight or branched chain
alkynyl (C2-Ce), aryl, substituted aryl, and arylalkyl;
R1 is selected from the group consisting of straight or branched chain alkyl (Ci-Cβ),
straight or branched chain alkenyl (C2-C6), straight or branched chain alkynyl (C2-
Cβ), aryl, substituted aryl, and arylalkyl;
R2 through R5 are independently selected from the group consisting of hydrogen,
straight or branched chain alkyl (Ci-Ce), straight or branched chain alkenyl (C2-C6),
straight or branched chain alkynyl (C∑-Ce), aryl, substituted aryl, and arylalkyl;
N = 0 or 1 ;
Y = CH;
or those compounds wherein R and R1 combine to form a C3-C5 alkylene or alkenylene bridge U-V-W-X, resulting in the structure represented by formula 2,
Figure imgf000022_0001
wherein X = CH2,-
m = 0, 1 , 2;
or those compounds wherein R and R1 combine to form a C3-C5 alkylene or
alkenylene bridge U-V-W-X, and ring memebers N and Y do not connect to form a
bridge, resulting in the basic structure represented by formula 3,
Figure imgf000022_0002
wherein ring member N is saturated and ring member Y is saturated or may
combine together with R5 to form a carbon-hydrogen bond with the ring carbon to
which it is attached;
its optical isomers and pharmaceutically-acceptable acid or base addition salt
thereof;
which is effective for alleviation of said condition; such a method-of-treating a living animal for alleviation of a condition
treatable by a neuronal nicotinic receptor antagonist selected from the group
consisting of Tourette's syndrome, anxiety disorders, Schizophrenia, drug
abuse, nicotine abuse, cocaine abuse, dyskinesia (Morbus Huntington, L-DOPA-
induced), attention deficit hyperactivity disorder (ADHD), Alzheimer's disease,
Parkinson's disease, and pain, comprising the step of administering to the living
animal an amount of a compound selected from those of formula 1 ,
Figure imgf000023_0001
1
wherein
R is selected from the group consisting of hydrogen, straight or branched chain
alkyl (Ci-Ce), straight or branched chain alkenyl (C2-Ce), straight or branched chain
alkynyl (C2-Ce), aryl, substituted aryl, and arylalkyl;
R1 is selected from the group consisting of straight or branched chain alkyl (Ci-Ce),
straight or branched chain alkenyl (C∑-Cβ), straight or branched chain alkynyl (C2-
Ce), aryl, substituted aryl, and arylalkyl; R2 through R5 are independently selected from the group consisting of hydrogen,
straight or branched chain alkyl (Ci-Ce), straight or branched chain alkenyl (C2-Ce),
straight or branched chain alkynyl (C2-Ce), aryl, substituted aryl, and arylalkyl;
N = 0 or 1 ;
Y = CH;
or those compounds wherein R and R1 combine to form a C3-C5 alkylene or
alkenylene bridge U-V-W-X, resulting in the structure represented by formula 2,
Figure imgf000024_0001
wherein X = CH2;
m = 0, 1 , 2;
or those compounds wherein R and R1 combine to form a C3-C5 alkylene or
alkenylene bridge U-V-W-X, and ring memebers N and Y do not connect to form a
bridge, resulting in the basic structure represented by formula 3,
Figure imgf000025_0001
wherein ring member N is saturated and ring member Y is saturated or may
combine together with R5 to form a carbon-hydrogen bond with the ring carbon to
which it is attached;
its optical isomers and pharmaceutically-acceptable acid or base addition salt
thereof;
which is effective for alleviation of said condition; and
such a pharmaceutical composition consisting of a compound selected from
those of formula 1 ,
Figure imgf000025_0002
wherein
R is selected from the group consisting of hydrogen, straight or branched chain
alkyl (Ci-Ce), straight or branched chain alkenyl (d-Cβ), straight or branched chain
alkynyl (C2-Ce), aryl, substituted aryl, and arylalkyl; R1 is selected from the group consisting of straight or branched chain alkyl (Ci-Ce),
straight or branched chain alkenyl (C2-Ce), straight or branched chain alkynyl (C2-
Cβ), aryl, substituted aryl, and arylalkyl;
R2 through R5 are independently selected from the group consisting of hydrogen,
straight or branched chain alkyl (Ci-Cβ), straight or branched chain alkenyl (C∑-Cβ),
straight or branched chain alkynyl (C2-Ce), aryl, substituted aryl, and arylalkyl;
N = 0 or 1 ;
Y = CH;
or those compounds wherein R and R1 combine to form a C3-C5 alkylene or
alkenylene bridge U-V-W-X, resulting in the structure represented by formula 2,
Figure imgf000026_0001
wherein X = CH∑;
m = 0, 1 , 2; or those compounds wherein R and R1 combine to form a C3-C5 alkylene or
alkenylene bridge U-V-W-X, and ring memebers N and Y do not connect to form a
bridge, resulting in the basic structure represented by formula 3,
Figure imgf000027_0001
wherein ring member N is saturated and ring member Y is saturated or may
combine together with R5 to form a carbon-hydrogen bond with the ring carbon to
which it is attached;
its optical isomers and pharmaceutically-acceptable acid or base addition salt
thereof;
in combination with one or more pharmaceutically-acceptable diluents,
excipients, or carriers.
DETAILED DESCRIPTION OF THE INVENTION
The following details and detailed Examples are given by way of illustration only, and are not to be construed as limiting.
Overall synthetic scheme and table for the 6-Azabicyclo[3.2.1 ]octanes
(belonging to structure of formula 1 of the Summary): Scheme 1
Figure imgf000028_0001
Table 1 6-Azabicyclo[3.2.1]octanes 1-1 to 1-8
Figure imgf000029_0001
Example 1.
1,exσ-3,5-Trimethyl-6-azabicyclo[3.2.1]octane hydrochloride (1-1 ).
a) 1 ,exo-3,5-Trimethyl-6-azabicyclo[3.2.1]oct-6-ene (5-1 ).
A mixture of of 1 ,3,3, zYat7s-5-tetramethylcyclohexanamine (4-1) (3.88 g, 25
mmol), K2CO3 (28 g, 0.2 mol) and lead tetraacetate (22,2 g, 50 mmol) in dry
benzene (1 25 ml) was stirred for 3 h while boiling at reflux. Then it was cooled
with ice water and filtered. The precipitate was washed with diethyl ether and the
filtrate evaporated under reduced pressure. The oily residue was separated by
column chromatography on silica gel (dichlorometane - /sσ-propyl alcohol, 20 : 1 ,
10 : 1 ). A fraction with Rf 0.7 (EtOAc) was collected to give after concentration
under reduced pressure 1 .0 g (26%) of imine 5-1 as an amber oil.
1H NMR (CDC , TMS) δ: 0.86 (3H, d, 6 Hz, 3-CHs), 0.90-1 .80 (7H, m, ring CH);
1 .12 (3H, s, I -CH3); 1 .34 (3H, s, 5-CHs) and 7.36 ppm (1 H, s, HC = ).
b) 1 ,e o-3,5-Trimethyl-6-azabicycIo[3.2.1]octane hydrochloride (1 -1 ).
A solution of imine 5-1 (0.8 g, 5.3 mmol) in MeOH (2 ml) was added dropwise to a
suspension of sodium borohydride (0.4 g, 10.6 mmol) in MeOH (6 ml). The mixture
was stirred at room temperature for 24 h, then 10 ml of 5% aqueous NaOH was
added. The mixture was extracted with diethyl ether. The organic phase was
washed with saturated aqueous NaCI and dried over NaOH pellets. The filtered
solution was treated with dry HCI solution in diethyl ether, evaporated under
reduced pressure and the residue was recrystallized from dry CH3CN to give
compound 1-1 as a colorless solid (0.33 g, 35%). 1H NMR (CDCΪ3, TMS) δ: 0.96 (3H, d, 6 Hz, 3-CHs), 0.95-1.15 (1 H, m, 2-CH); 1.11
(3H, s, 1 -CH3); 1.41 (1 H, d, 12.4 Hz, 8-CH); 1 .55-1.70 (1 H, m, 2-CH); 1.57 (3H,
s, 5-CH3); 1.70-1.90 (2H, m, 4-CH and 8-CH); 2.00-2.30 (2H, m, 3-CH and 4-CH);
3.00-3.25 (2H, m, 7-CH2) and 9.30-9.85 ppm (2H, br s, NH2 +).
Example 2.
5-EthyI-1 ,exo-3-dimethyl-6-azabicycIo[3.2.1]octane hydrochloride (1-2).
a) 1-Azido-1-ethyl-3,3,fra/?s-5-trimethylcyclohexane (7).
A cooled ( ~0 °C) mixture of 1 -ethyl-3,3,zVaΛS-5-trimethylcyclohexanol (6) (3.3 g,
18.1 mmol), sodium azide (2.36 g, 36.3 mmol) and trif luoroacetic acid (10.7 ml) in
chloroform (50 ml) was stirred for 24 h. Then it was made basic by diluted aqueous
ammonia addition. The organic phase was separated, washed with water and dried
over K2CO3. Filtration and solvent evaporation under reduced pressure gave an oily
residue which was separated by flash chromatography on silica gel eluting with
light petroleum ether to give azide 7 (2.0 g, 56%) as light colorless oil.
1H NMR (CDCI3, TMS) δ: 0.64 (1 H, d, 14 Hz, ring CH); 0.85-2.15 (8H, m, ring CH
and Et-CH2); ); 0.90 (3H, d, 7 Hz, 5-CH3); 0.92 (3H, s, 3-CH3eq); O.97 (3H, t, 7.5
Hz, Et-CHs) and 1.10 ppm (3H, s, 3-CH3ax).
b) 1-Ethyl-3,3,fra/ϊs-5-trimethyIcyclohexanamine (4-2).
Azide 7 (1.97 g, 10 mmol) solution in diethyl ether (10 ml) was added dropwise to
a suspension of lithium aluminum hydride (1.13 g, 30 mmol) in diethyl ether (30
ml). The mixture was stirred for 20 h at room temperature. Then it was carefully quenched with 10% aqueous NaOH. The organic phase was separated and the
aqueous phase extracted with diethyl ether. The combined organic phases were
washed with saturated aqueous NaCI and dried over NaOH. Filtration and solvent
evaporation under reduced pressure gave amine 4-2 (1 .36 g, 80%) as an oil.
1H NMR (CDCI3, TMS) δ: 0.55-2.15 (9H, m, ring CH and Et-CH2); 0.88 (3H, s, 3-
CHseq); 0.89 (3H, d, 6.5 Hz, 5-CHs); 0.89 (3H, t, 7 Hz, Et-CHs) and 1 .12 ppm (3H,
Figure imgf000032_0001
c) 5-Ethyl-1 ,exo-3-dimethyl-6-azabicycIo[3.2.1]octane hydrochloride (1 -2).
Prepared in 30% yield from imine 5-2 according to procedure described in Example
1 b. Colorless solid.
'H NMR (CDC , TMS) δ: 0.95-1 .1 5 (7H, m, ring CH, 3-CH3 and CH3-Et); 1 .1 2 ( 3H,
s, 1 -CHs); 1 .48 (1 H, d, 13.6 Hz, 8-CH); 1 .55-1 .76 (3H, m, ring CH and CH2-Et);
1.84-2.04 (2H, m, ring CH) and 2.04-2.28 (2H, m, 4,8-CH); 3.14 (2H, m, 7-CH2)
and 9.40 ppm (2H, br s, NH2 +).
d) 5-Ethyl-1 ,e o-3-dimethyl-6-azabicyclo[3.2.1]oct-6-ene (5-2).
Prepared in 32% yield from amine 4-2 according to procedure described in Example
1 a. An oil.
1H NMR (CDCI3, TMS) δ: 0.82-0.95 (1 H, m, ring CH); 0.91 (3H, d, 6 Hz, 3-CH3),
0.94 (3H, t, 7.5 Hz, Et-CHs); 1 .1 5-1 .75 (6H, m, ring CH); 1 .1 5 (3H, s, 1 -CHs);
1 .71 (2H, q, 7.5 Hz, Et-CH2) and 7.38 ppm (1 H, s, HC = ). Example 3.
exo-3-Ethyl-1,5-dimethyI-6-azabicyclo[3.2.1]octane hydrochloride (1-3).
a) te/f-Butyl fra/7s-5-ethyl-1,3,3-trimethylcyclohexyIcarbamate (8-1).
To a solution of 1 ,3,3-trimethyl-tra/?s-5-ethylcyclohexanamine hydrochloride (4-3)
(1.54 g, 7.5 mmol) in THF (20 ml) was added Na2COs (3.18 g, 30 mmol) and the
mixture was stirred for 30 min. Then it was cooled with ice water, di-ferf-butyl
dicarbonate (1.7 g, 7.65 mmol) was added and stirring was continued for 20 h.
Water was added and the mixture was twice extracted with diethyl ether. The
combined extracts were washed with saturated aqueous NaCI, dried over MgSO
and evaporated. The solid residue was treated with hexane, filtered and washed
with hexane.to give carbamate 8-1. Additional amount of 8-1 was isolated after the
filtrate was evaporated and treated with acetonitrile. Carbamate 8-1 (1.18 g, 57%)
was obtained as a colorless solid with mp 70-71 °C.
'H NMR (CDCIs, TMS) δ: 0.65-1.65 (7H, m, CH2-Et and ring CH); 0.88 (3H, t, 6.5
Hz, CHa-Et); 0.88 and 0.99 (both 3H, s, 3,3-CH3); 1.42 (9H, s, t-Bu);
1.85 (1 H, dq, 13.5 and 2.5 Hz, 6-CHβq); 2.24 (1 H, d, 14 Hz, 2-CHβq) and 4.30 ppm
(1 H, br s, NH).
b) te/ϊ-Butyl exσ-3-ethyl-1 ,5-dimethyl-6-azabicyclo[3.2.1]octane-6-carboxylate
(9-1). To a mixture of carbamate 8-1 (1.05 g, 3.85 mmol) and iodine (1.95 g, 7.7 mmol)
in dry benzene (35 ml) was added lead tetraacetate (3.92 g, 8.85 mmol) in one portion. The mixture was stirred while boiling at reflux for 4 h then cooled with ice
water and filtered. The precipitate was washed with diethyl ether and the filtrate
carefully washed with saturated aqueous potassium metabisulfite followed by
saturated aqueous NaHCO3. The organic phase was washed with saturated
aqueous NaCI, dried over MgSO and evaporated. The residue was purified by flash
chromatography on silica gel (light petroleum ether - ethyl acetate, 20:1 ) to give
compound 9-1 (0.76 g, 73%) as a colorless oil.
1H NMR (CDCIa, TMS) δ: 0.86 (3H, t, 6.5 Hz, CHs-Et); 1.00 (3H, s, 1-CHs); 1.00-
1.80 (7H, m, CH2-Et and ring CH); 1.46 (12H, s, t-Bu and 5-CH3); 1.95-2.45 (2H,
m, ring-CH); 3.06 and 3.36 ppm (both 1 H, d, 1 1 Hz, 7-CH2).
c) e o-3-Ethyl-1 ,5-dimethyl-6-azabicycIo[3.2.1]octane hydrochloride (1-3).
Carbamate 9-1 (0.73 g, 2.7 mmol) was added to a solution of trifluoroacetic acid
(3 ml) in dichloromethane (15 ml) and the mixture was stirred at room temperature
for 10 h. The solution was evaporated under reduced pressure and the residue was
treated with 10% aqueous NaOH (5 ml) and extracted with diethyl ether. The
extract was washed with saturated aqueous NaCI and dried over NaOH. The
filtered solution was treated with dry HCI solution in diethyl ether. The solvent was
evaporated under reduced pressure and the residue was treated with dry
acetonitrile to give amine hydrochloride 1-3 as colorless solid (0.34 g, 62%).
1H NMR (CDC , TMS) δ: 0.85-2.45 (9H, m, 2, 4, 8- CH2, 3-CH and CH2-Et); 0.90
(3H, t, 7 Hz, CH3-Et); 1.12 ( 3H, s, 1 -CHs); 1 .59 (3H, s, 5-CH3); 3.13 (2H, t, 6 Hz,
7-CH2) and 9.55 ppm (2H, br s, NH2 +). Example 4.
1 ,3,3,5-Tetramethyl-6-azabicyclo [3.2.1]octane hydrochloride (1 -4).
a) te/ -Butyl 1 ,3,3,5,5-pentamethylcyclohexylcarbamate (8-2).
Prepared in 70% yield from 1 ,3,3,5,5-pentamethylcyclohexanamine hydrochloride
(4-4) according to the procedure described in Example 3a. Purified by flash
chromatography on silica gel (light petroleum ether - ethyl acetate, 20: 1 ). A
colorless oil.
1H NMR (CDCb, TMS) δ: 0.87 (6H, s, 3,5-CH3βq); 0.90-1 .45 (4H, m, 4-CH2 and
2,6-CHax); 1 .12 (6H, s, 3,5-CH3aχ); 1.27 (3H, s, 1 -CHs); 1 .42 (9H, s, t-Bu); 2.24
(2H, d, 1 5 Hz, 2,6-CHeq) and 4.30 ppm (1 H, br s, NH).
b) terf-Butyl 1 ,3,3,5-tetramethyl-6-azabicyclo[3.2.1]octane-6-carboxylate (9-2).
Prepared in 48% yield from carbamate 8-2 according to the procedure described in
Example 3b. A colorless oil.
1H NMR (CDCb, TMS) δ: 0.91 , 0.94 and 0.99 (total 9H, all s, 1 ,3,3-CHs); 0.80-
1.75 (5H, m, ring CH); 1 .34 and 1.52 (total 3H, both s, 5-CHs); 1 .41 and 1.44
(total 9H, both s, t-Bu); 1 .91 and 2.09 (total 1 H, both d, 14.5 Hz, 6-CH); 3.00 and
3.28 (one rotamer); and 3.03 and 3.33 (another rotamer; total 2H, all dd, 1 1 and 2
Figure imgf000035_0001
c) 1 ,3,3,5-Tetramethyl-6-azabicyclo [3.2.1]octane hydrochloride (1-4).
Prepared in 68% yield from carbamate 9-2 according to the procedure described in
Example 3c. Colorless solid. 1H NMR (CDCb, TMS) δ: 1 .00, 1 .13 and 1 .29 (total
9H, s, 1 ,3,3-CH3); 1 .25-1 .65 (4H, m, 2-CH2 and 4,8-CH ); 1 .64 (3H, s, 5-CHs); 1.81 (1 H, dt, 12.4 and 2.3 Hz, 4-CH); 2.21 (1 H, d, 14.5 Hz, 8-CH); 3.10-3.40
(2H, m, 7-CH2); 9.10 and 9.90 ppm (total 2H, both br s, NH2 +).
Example 5.
1 ,3,3,5,6-Pentamethyl-6-azabicyclo [3.2.1]octane hydrochloride (1-5).
a) Methyl 1,3,3,5-tetramethyl-6-azabicyclo[3.2.1]octane-6-carboxylate (11).
Prepared in 50% yield from methyl 1 ,3,3,5,5-pentamethylcyclohexylcarbamate (10)
according to the procedure described in Example 3b. A colorless oil.
1H NMR (CDCb, TMS) δ: 0.87 and 0.96 (total 9H, both s, 1 ,3,3-CH3); 1.00-1.70
(4H, m, 2-CH2 and 4,8-CH); 1.33 and 1.46 (total 3H, both s, 1-CHs); 1.70-1.20
(2H, m, 4,8-CH); 3.04 and 3.34 (major rotamer) and 3.10 and 3.39 (minor rotamer;
total 2H, all dd, 1 1.5 and 1.5 Hz, 7-CH2); 3.59 (major) and 3.64 (total 3H, both s,
OCHs).
b) 1 ,3,3,5,6-Pentamethyl-6-azabicyclo [3.2.1]octane hydrochloride (1-5).
A solution of carbamate 11 (1.0 g, 4.44 mmol) in diethyl ether (10 ml) was added
to a suspension of lithium aluminum hydride (0.34 g, 9 mmol) in diethyl ether (25
ml). The mixture was stirred for 20 h at room temperature. Then it was cooled with
ice water and carefully quenched with 10% aqueous NaOH. The organic phase was
separated and the aqueous phase extracted with diethyl ether. The combined
organic phases were washed with saturated aqueous NaCI and dried over NaOH.
Filtered solution was treated with an excess amount of dry HCI solution in diethyl
ether. The solvent was evaporated under reduced pressure and the residue was
treated with dry acetonitrile and diethyl ether (2:1 ), and cooled in refrigerator for 24 h. The precipitate was filtered and washed with diethyl ether to give amine
hydrochloride 1-5 (0.25 g, 26%) as a colorless solid.
1H NMR (CDCb, TMS) δ: 1.03, 1.09, 1.16 and 1.22 (total 9H, all s, 1, 3,3-CH3);
1.44 (3H, s, 5-CH3); 1.50-2.50 (6H, m, 2, 4, 8- CH2); 2.73 (d, 5 Hz) and 2.80
(total 3H, d, 5.5 Hz, N-CHa); 2.55 (m) and 2.94 (total 1H, dd, 12 and 6 Hz, 7-CH);
3.73 (dd, 12 and 8.5 Hz) and 4.07 (total 1H, dd, 13 and 7 Hz, 7-CH); 9.50 and
10.80 ppm (total 1 H, br s, NH+).
Example 6.
5-Ethyl-1,3,3-trimethyl-6-azabicyclo[3.2.1]octane hydrochloride (1-6).
a) 5-Ethyl-1,3,3-trimethyl-6-azabicycIo[3.2.1]oct-6-ene (5-3).
Prepared in 28% yield from 1-ethyl-3,3,5,5-tetramethylcyclohexanamine (4-5)
according to the procedure described in Example 1a. An oil.
1H NMR (CDCb, TMS) δ: 0.93 (3H, s, 3-CH3); 0.94 (3H, t, 7.4 Hz, Et-CHs); 0.98
(3H, s, 3-CHa); 1.15 (3H, s, 1-CHa); 1.20-1.50 (5H, m, ring CH); 1.57 (1H, dt,
12.4 and 2 Hz, ring CH); 1.69 (2H, dq, 7.5 and 2.8 Hz, Et-CH2) and 7.47 ppm (1 H,
s, HC = ).
b) 5-Ethyl-1,3,3-trimethyl-6-azabicyc!o[3.2.1]octane hydrochloride (1-6).
Prepared in 33% yield from imine 5-3 according to the procedure described in
Example 1b.
Colorless solid.
1H NMR (CDCb, TMS) δ: 1.01 (3H, s, 3-CH3); 1.03 (3H, t, 7.5 Hz, CH3-Et); 1.13
and 1.31 (both 3H, s, 1,3-CH3); 1.25-1.35 (1H, m, ring CH); 1.35-1.65 (4H, m, CH2-Et and ring CH); 1.69 (1 H, d, 12 Hz, 2-CH); 1 .92-2.12 (2H, m, 4,8-CH); 3.05-
3.45 (2H, m, 7-CH2): 9.05 and 9.65 ppm (both 1 H, br s, NH2 +).
Example 7.
1 , exo-3,5, e o,e/7oO-7-Tetramethyl-6-azabicyclo[3.2.1]octane hydrochloride (1-7).
a) fe/τ-Butyl c/s-3-ethyl-1 ,3,fra/7s-5-trimethylcyclohexylcarbamate (8-3).
Prepared in 81 % yield from 1 ,3,5-trimethyl-c/s-3-ethylcγclohexanamine
hydrochloride (4-6) according to the procedure described in Example 3a. Purified by
flash chromatography on silica gel (light petroleum ether - ethyl acetate, 20:1 ). A
colorless oil.
1H NMR (CDCb, TMS) δ: 0.63 (1 H, d, 12.5 Hz, ring CH); 0.70-0.90 (1 H, m, ring
CH); 0.79 (3H, t, 7.5 Hz, CHa-Et); 0.86 (3H, d, 6.4 Hz, 5-CHs); 1.28 (3H, s, 3-
CHs); 1.25-1.85 (6H, m, ring CH and CH2-Et); 1.41 (9H, s, t-Bu); 1.52 (3H, s, 1-
CH3); 2.35 (1 H, d, 12.5 Hz, 2-CH) and 4.31 ppm (1 H, br s, NH).
tert-Butyl 1 , exσ-3,5, ej o,e/7oO-7-tetramethyl 6-azabicyclo[3.2.1]octane-6- carboxylate (9-3).
Prepared in 57% yield from carbamate 8-3 according to the procedure described in
Example 3b. A colorless oil.
1H NMR (CDCb, TMS) δ: 0.60-1.85 (6H, m, ring CH); 0.85-1.15 (6H, m, 1 ,3-CHs);
1 .35-1 .55 (6H, m, 5,7-CHa); 1.45 (9H, s, t-Bu); 2.06 and 2.27 (total 1 H, m, ring
CH); 3.36 and 3.51 ppm (total 1 H, m, 7-CH).
1 , exσ-3,5, exσ,e /o-7-Tetramethyl-6-azabicyclo[3.2.1]octane hydrochloride (1-7).
Prepared in 70% yield from carbamate 9-3 according to the procedure described in
Example 3c. A colorless solid. 1H NMR (CDCb, TMS) δ: 0.96 (3H, d, 5.8 Hz, 3-CH3); 1.00 (3H, s, 1-CHs); 1.00-
1.15 (1 H, m, 2-CH); 1 .36 (1 H, d, 12 Hz, 8-CH); 1.43 (3H, d, 7.4 Hz, 7-CH3); 1.55-
1.75 (2H, m, 2-CH and 4-CH); 1 .62 (3H, s, 5-CHs); 1.90 (1 H,
d, 12.6 Hz, 8-CH); 2.15-2.35 (2H, m, 3-CH and 4-CH); 3.65 (1 H, m, 7-CH); 9.00
and 9.95 ppm (total 2H, both br s, NH2+).
Example 8.
1, e o-3,5-Trimethyl-e o/eπcf'o-7-phenyl-6-azabicyclo[3.2.1]octane hydrochloride
(1-8).
a) 3-BenzyI-3,5-dimethylcyclohexanone (13).
To a cooled (-20 °C) 1 M benzylmagnesium bromide solution in diethyl ether (50 ml)
under argon was added CuCI (0.52 g, 5.3 mmol) and the mixture was stirred for 5
min. Then a solution of 3,5-dimethyl-2-cyclohexen-1 -one (12) (4.4 g, 35.1 mmol) in
diethyl ether (15 ml) was added dropwise keeping the temperature below -10 °C.
The mixture was stirred for 2 h and quenched with 10% aqueous acetic acid (40
ml). The organic layer was separated, washed with water, saturated aqueous
NaHCOβ and saturated aqueous NaCI, and dried over MgSO4. Filtration and
concentration in vacuo afforded oily residue what was separated by flash
chromatography on silica gel (light petroleum ether - ethyl acetate, 10:1 ).
Cyclohexanone 13 (4.0 g, 53%) was obtained as a colorless oil.
1H NMR (CDCb, TMS) δ: 0.92 (3H, s, 3-CHs); 1.06 (3H, d, 6 Hz, 5-CHs), 1.10-2.45 (7H, m, ring CH); 2.42 and 2.56 (total 2H, both d, 13 Hz, CH2Ph) and 7.05-7.35
ppm (5H, m, Ph).
b) c/s-3-Benzyl-1,3,.7'aΛs-5-trimethylcyclohexanol (14).
A solution of ketone 13 (3.9 g, 18.1 mmol) in diethyl ether (10 ml) was added
dropwise to 1 M MeMgl in diethyl ether (40 ml). The mixture was stirred for 1 h at
room temperature. Etheral extract obtained after traditional workup for Grignard
reactions was dried over Na2SO4, filtered and evaporated to give an oily residue
what was purified by flash chromatography on silica gel (light petroleum ether -
ethyl acetate). Cyclohexanol 14 (3.2 g, 76%) was obtained as a colorless oil.
1H NMR (CDCb, TMS) δ: 0.75 (3H, s, 3-CHs); 0.95-1.25 (3H, m, ring CH); 0.92
(3H, d, 6.6 Hz, 5-CHs), 1.23 (3H, s, I-CH3); 1.45-1 .75 (3H, m, ring CH); 2.05-
2.25 (1 H, m, 5-CH); 2.77 and 3.04 (both 1 H, d, 13 Hz, CH2Ph) and 7.05-7.35 ppm
(5H, m, aryl CH).
c) N-(c/s-3-Benzyl-1 ,3,;f/-3Λs-5-trimethylcyclohexyl)-2-chIoroacetamide (15).
Sulfuric acid (2.1 ml, 3.83 g, 39 mmol) was added dropwise to a stirred solution of
cyclohexanol 14 (3.0 g, 13 mmol) and chloroacetonitrile (4.0 g, 52 mmol) in acetic
acid (2.1 ml) while cooling with ice water. The mixture was stirred for 24 h at room
temperature then poured into ice water (10 ml). The mixture was neutralised with
20% aqueous NaOH and extracted with diethyl ether (3x15 ml). The combined
organic phases were washed with saturated aqueous NaCI and dried over MgSO4.
The extract was filtered and the solvent evaporated. The residue was purified by
flash chromatography on silica gel eluting with a mixture of light petroleum ether and ethyl acetate (10: 1 ) to give amide 15 (1.32 g, 33%) as a colorless oil.
1H NMR (CDCb, TMS) δ: 0.73 (3H, s, 3-CHs); 0.90-1.40 (3H, m, ring CH); 0.98
(3H, d, 6.6 Hz, 5-CHs), 1.42 (3H, s, 1 -CHs); 1.63 (1 H, m, ring CH); 1.80-2.05 (1 H,
m, 5-CH); 2.12 (1 H, dq, 13.8 and 3 Hz, 6-CH); 2.33 (1 H, d, 12.7 Hz, CH2Ph); 2.51
(1 H, dt, 15 and 2.2 Hz, 2-CH); 3.17 (1 H, d, 12.7 Hz, CH2Ph); 3.95 and 3.96 (total
2H, both s, CH2CO); 6.52 (1 H, br s, NH) and 7.00-7.35 ppm (5H, m, aryl CH).
d) c/s-3-Benzyl-1 ,3,frans-5-trimethylcyclohexanamine hydrochloride (4-7).
A solution of amide 15 (0.62 g, 2 mmol) and thiourea (0.18 g, 2.4 mmol) in a
mixture of ethanol (5 ml) and acetic acid (1 ml) was refluxed for 10 h. The reaction
mixture was cooled to room temperature and 20 ml of 10% aqueous NaOH was
added while stirring. The resulting mixture was extracted with diethyl ether (3x 10
ml). The combined extracts were washed with saturated aqueous NaCI, dried over
NaOH, filtered and treated with dry HCI solution in diethyl ether. The solvent was
evaporated under reduced pressure and the residue treated with dry diethyl ether to
give amine hydrochloride 4-7 (0.33 g, 35%) as a colorless solid.
1H NMR (CDCb, TMS) δ: 0.68 (3H, d, 6.5 Hz, 5-CH3); 0.70-1 .30 (3H, m, ring CH);
0.73 (3H, s, 3-CHs); 1.28 (3H, s, 1-CHs); 1.50 (1 H, d, 15.4 Hz, ring CH); 1.60-
1 .85 (1 H, m, ring CH); 2.05 (1 H, d, 16 Hz, ring CH); 2.15-2.50 (1 H, m, 5-CH);
2.47 and 3.33 (both 1 H, d, 12.8 Hz, CH2Ph); 7.00-7.35 (5H, m, aryl CH) and 8.42
ppm (3H, br s, NHs+).
e) 1 , exo-3,5-Trimethyl-7-phenyl-6-azabicyclo[3.2.1]oct-6-ene (5-4).
Prepared in 40% yield from free amine 4-7 according to the procedure described in Example 1 a. An oil.
Η NMR (CDCb, TMS) δ: 0.94 (3H, d, 6.6 Hz, 3-CH3); 0.90-1.15 (2H, m, ring CH);
1.26 (3H, s, 1-CHs); 1.30-1.90 (5H, m, ring CH); 1.43 (3H, s, 5-CH3) and 7.30-
7.65 ppm (5H, m, aryl CH).
f) 1 , exσ-3,5-Trimethyl-e o,e/7oO-7-phenyl-6-azabicyclo[3.2.1 ]octane
hydrochloride (1-8).
Prepared in 33% yield from imine 5-4 according to the procedure described in
Example 1 b.
Colorless solid.
1H NMR (CDCb, TMS) δ: 0.75-1.95 (4H, m, ring CH); 0.86 (3H, d, 5,8 Hz, 3-CH3);
1.20 (3H, s, 1 -CH3); 1.56 (3H, s, 5-CH3); 1.99 (1 H, d, 14.4 Hz, 8-CH); 2.05-2.15
(1 H, m, ring CH); 2.20-2.30 (1 H, m, ring CH); 4.57 (1 H, m, 7-CH); 7.24 and 7.65
(total 5H, both br s, Ph); 9.15 and 10.40 ppm (total 2H, both br s, NH2 +).
Overall synthetic scheme and table for 6-Azabicyclo[3.2.1 ]nonanes
(belonging to the structure of formula 1 of the Summary).
Scheme 2
Table 2 6-Azabicyclo[3.2.1 ]nonane 1-9
Figure imgf000044_0001
Example 9.
1 ,5,exσ-7-Trimethyl-2-azabicyclo[3.3.1]nonane hydrochloride (1-9).
a) 2-{c/s-3-[(2-Chloroacetyl)amino]-1 ,3,fra/?s-5-trimethylcyclohexyl}acetic acid
(16).
To a solution of 1 .5 g (4.9 mmol) of N-(c/s-3-BenzyI-1 ,3,t7at7s-5-
trimethylcyclohexyl)-2-chloroacetamide (obtained from a fraction with Rf 0.7-0.8
(Hexanes-EtOAc, 2:1 ) separated after the synthesis of compound 15, Example 8c)
in a mixture of acetonitrile (16 ml), tetrachloromethane (16 ml) and water (23 ml)
was added sodium periodate (10.5 g, 49 mmol) and ruthenium dioxide (7 mg, 0.06
mmol). The mixture was stirred at room temperature for 72 h, then it was filtered
and the filter cake was washed with dichloromethane. The organic phase of the
filtrate was separated and the aqueous phase was extracted with dichloromethane.
The combined organic phases were dried over CaC , filtered and evaporated. The residue was purified by flash chromatography on silica gel eluting with chloroform
to give acid 16 (0.55 g, 41 %) as an oil.
Η NMR (DMSO-de, TMS) δ: 0.8-2.6 (7H, m, ring CH); 0.84 and 0.85 (total 3H, d,
6 Hz, 5-CHs); 0.92 and 1.01 (total 3H, s, 1-CHs); 1.21 and 1.22 (total 3H, s, 3-
CHs); 2.19 and 2.39 (total 2H, both d, 13.5 Hz, CH2CO); 3.97 ppm (2H, s, CH2CI);
7.57 and 7.70 (total 1 H, both br s, NH) and 12.05 ppm (1 H, br s, COOH).
b) Ethyl 2-{c/s-3-[(2-chloroacetyl)amino]-1 ,3,fra ιs-5-trimethylcyclohexyl}acetate
(17).
Thionyl chloride (0.73 ml, 10 mmol) was added dropwise to a solution of acid 16
(0.55 g, 1 .99 mmol) in dry ethanol (5 ml), while cooling with ice water. The
resulting solution was stirred for 15 h at room temperature then evaporated under
reduced pressure. The residue was purified by flash chromatography on silica gel
eluting with a mixture of light petroleum ether and ethyl acetate (6: 1 ) to give ethyl
ester 17 (0.32 g, 54%) as an oil.
1H NMR (CDCb, TMS) δ: 0.7-1.6 (4H, m, ring CH); 0.88-0.94 (3H, m, 5-CH3); 1.04
and 1 .14 (total 3H, s, 1 -CHs); 1.25 (2H, t, 7 Hz, CHs-ethyl); 1.35 and 1.36 (total
3H, s, 3-CH3); 1 .6-1.8 (1 H, m, 5-CH); 2.05-2.35 (2H, m, ring CH); 2.16 and 2.79
(total 2H, d, 13 Hz, CH2CO); 3.92 and 3.95 (total 2H, s, CH2CI); 4.12 (2H, q, 7 Hz,
CH2O); 6.42 and 7.28 ppm (total 1 H, br s, NH).
c) 1 ,5,exσ-7-Trimethyl-2-azabicyclo[3.3.1]nonan-3-one (18).
A solution of ethyl ester 17 (0.32 g, 1.07 mmol) and thiourea (0.098g, 1 .3 mmol)
in a mixture of ethanol (5 ml) and acetic acid (1 .2 ml) was refluxed for 20 h. The reaction mixture was cooled to room temperature and the solvents evaporated.
10% aqueous NaOH was added and the mixture was extracted with chloroform (3x
10 ml). The combined organic extracts were dried over CaC , filtered and
evaporated. The residue was purified by flash chromatography on silica gel eluting
with a mixture of light petroleum ether and ethyl acetate (6:1 , 3: 1 ). A fraction with
Rf 0,4 (Hexane-EtOAc, 2:1 ) was collected to give lactam 18 (0.12 g, 39%) as a
colorless solid with mp 176-177 °C.
1H NMR (CDCb, TMS) δ: 0.89 (3H, d, 5.8 Hz, 7-CHs); 0.75-1 .05 (3H, m, ring CH);
0.99 (3H, s, 5-CHs); 1.20 (3H, s, 1 -CHs); 1.24-1.36 (1 H, m, ring CH); 1.45-1.60
(2H, m, ring CH); 1 .60-1 .84 (1 H, m, 7-CH); 2.14 (2H, s, 4-CH2) and 5.40 ppm (1 H,
br s, NH).
d) 1 ,5,7-Trimethyl-2-azabicyclo[3.3.1]nonane hydrochloride (1-9).
1 M Borane solution in tetrahydrofuran (2 ml, 2 mmol) was added to a solution of
lactam 18 (0.07 g, 0.385 mmol) in tetrahydrofuran (2 ml) and refluxed for 15 h.
The mixture was cooled to room temperature and made acidic by addition of cone,
aqueous HCI. Solvents were evaporated under reduced pressure and hexane (10
ml) and 20% aqueous NaOH (10 ml) were added to the residue. The organic phase
was separated and the aqueous phase was extracted with hexane (2x 5 ml). The
combined organic phases were washed with saturated aqueous NaCI (10 ml) and
dried over NaOH. The extract was filtered and dry HCI solution in diethyl ether was
added. The solvent was evaporated and the residue was treated with diethyl ether
(5 ml). The precipitate was collected on a filter to give amine hydrochloride 1-9 (0.02 g, 25%) as a colorless solid.
1H NMR (CDCb, TMS) δ: 0.80-1.85 (7H, m, ring CH); 0.88 (3H, d, 6.5 Hz, 7-CHs);
0.96 (3H, s, 5-CHs); 1.50 (3H, s, 1-CHs); 2.10-2.40 (2H, m, 7-CH and 8-CH);
3.15-3.35 and 3.30-3.55 (both 1H, m, 3-CH2); 9.15 and 9.55 ppm (both 1H, brs,
NH2 +).
Overall synthetic scheme and table for 1-Azaspiro compounds (belonging to
the structure of formula 3 of the Summary).
Scheme 3
Figure imgf000047_0001
Table 3
Figure imgf000048_0001
Example 10.
7,7,9,9-Tetramethyl-1 -azaspiro[4.5]decane hydrochloride (3-1 ).
a) 3,3,5,5-Tetramethyl-l-(2-phenylethyl)cyclohexanoI (20-1).
A solution of 3,3,5,5-pentamethyIcyclohexanone (19) (1.54 g, 10 mmol) in diethyl
ether (10 ml) was added to 0.85 M solution of phenylethylmagnesium bromide in
diethyl ether (25 ml, 20 mmol), while cooling with an ice bath. The resulting
mixture was stirred for 0.5 h and saturated aqueous NH4CI (30 ml) was added
thoroughly. The organic phase was separated and the aqueous phase was washed
with diethyl ether (2x20 ml). The combined organic phases were washed with
saturated aqueous NaCI solution (20 ml) and dried over MgSO4. Filtration and
evaporation of the solution gave a residue what was purified by flash
chromatography on silica gel eluting with a mixture of light petroleum ether and
ethyl acetate (10: 1 ) to give cyclohexanol 20-1 (2.1 g, 82%) as an oil.
'H-NMR (CDCb, TMS) δ: 0.91 (6H, s, 3,5-CH3); 1 .23 (6H, s, 3,5-CHs); 1.0-1 .6
(7H, m, ring protons and OH); 1 .6-1.8 (2H, m, PhCH∑CH∑); 2.6-2.8 (2H, m,
PhCH∑CH∑) and 7.0-7.4 ppm. (5H, m, Ph). b) 2-Chloro-N-[3,3,5,5-tetramethyl-1-(2-phenylethyl)cyclohexyl]acetamide (21-1 ).
Prepared in 96% yield from cyclohexanol 20-1 according to the procedure
described in Example 8c. A colorless oil.
1H-NMR (CDCb, TMS) δ: 0.93 (6H, s, 3,5-CH3); 1.17 (6H, s, 3,5-CHs); 1.0-1 .5
(4H, m, 4-CH2, 2,6-CH); 2.0-2.2 (2H, m, PhCH2CH2); 2.24 (2H, d, 14 Hz, 2,6-CH);
2.5-2.6 (2H, m, PhCH2CH2); 3.90 (2H, s, CH2CI); 6.60 (1 H, br s, NH) and 7.1 -7.3
ppm (5H, m, Ph).
c) 3-{1 -[{2-Chloroacetyl)amino]-3,3,5,5-tetramethylcycIohexyl}propanoic acid (22-
1).
Prepared 53% yield from amide 21-1 in according to the procedure described in
Example 9a. A colorless crystals with mp 130-131 °C.
1H-NMR (CDCb, TMS) δ: 0.92 (6H, s, 3,5-CHs); 1.17 (6H, s, 3,5-CHs); 1.0-1.5
(4H, m, 4-CH2, 2,6-CH,); 2.0-2.4 (6H, m, OCCH2CH2, 2,6-CH); 3.97 (2H, s, CH2CI)
and 6.6 ppm (1 H, br s, NH);
d) Ethyl 3-{1 -[(2-chloroacetyl)amino]-3,3,5,5-tetramethylcyclohexyl}propanoate
(23-1 ).
Prepared in 82% yield from acid 22-1 according to the procedure described in
Example 9b. An oil.
1H-NMR (CDCb, TMS) δ: 0.91 (6H, s, 3,5-CHs); 1.14 (6H, s, 3,5-CHs); 1.25 (3H, t,
7 Hz, CH3CH2O); 0.8-1 .6 (4H, m, 4-CH2, 2,6-CH); 2.0-2.4 (6H, m, OCCH2CH2, 2,6-
CH); 3.95 (2H, s, CH2CI); 4.1 1 (2H, q, 7 Hz, CH3CH2O) and 6.50 ppm (1 H, br s,
NH). e) 7,7,9,9-Tetramethyl-1 -azaspiro[4.5]decan-2-one (24-1 ).
Prepared in 54% yield from ester 23-1 according to the procedure described in
Example 9c. A colorless solid with mp 1 58-160 °C.
1H-NMR (CDCb, TMS) δ: 1 .01 (12H, s, 7,9-CHs); 1 .19 (1 H, d, 14 Hz, 8-CH); 1.27
(1 H, d, 14 Hz, 8-CH); 1 .45 (4H, s, 6,10-CH2); 2.02 (2H, t, 7.5 Hz, 4-CH2); 2.36
(2H, t, 7.5 Hz, 3-CH2) and 5.8 ppm (1 H, br s, NH).
f) 7,7,9,9-Tetramethyl-1-azaspiro[4.5]decane hydrochloride (3-1).
Prepared in 76% yield from spirolactam 24-1 according to the procedure described
in Example 9d. Colorless solid.
1H-NMR (CDC , TMS) δ: 1 .01 (6H, s, 7,9-CHs); 1.08 (6H, s, 7,9-CHs); 1 .23 (1 H, d,
14 Hz, 8-CH); 1.35 (1 H, d, 14 Hz, 8-CH); 1.8 (4H, br s, 6, 10-CH2); 2.0-2.2 (4H,
m, 3,4-CH2); 3.3 (2H, br s, 2-CH2) and 9.4 ppm (2H, br s, NH2 +).
Example 11.
8,8,10,10-Tetramethyl-1-azaspiro[5.5]undecane hydrochloride (3-2).
a) 3,3,5,5-Tetramethyl-1-(3-phenylpropyl)cyclohexanol (20-2).
Prepared in 90 ,% yield from ketone 19 according to the procedure described in
Example 10a. A colorless oil.
H-NMR (CDC , TMS) δ: 0.86 (6H, s, 3,5-CHs); 1 .19 (6H, s, 3,5-CH3); 1.0-1 .8
(1 1 H, m, ring protons, OH and PhCH2CH2CH2); 2.60 (2H, t, 7.5 Hz, PhCH∑CH∑CH∑)
and 7.1 -7.4 ppm (5H, m, Ph).
b) 2-Chloro-N-[3,3,5,5-tetramethyI-1-(3-phenylpropyl)cyclohexyl]acetamide (21-2).
Prepared in 37% yield from cyclohexanol 20-2 according to the procedure described in Example 8c. Colorless solid with mp 83-85 °C.
1H-NMR (CDCb, TMS) δ: 0.89 (6H, s, 3,5-CHs); 1.13 (6H, s, 3,5-CHs); 0.9-1.9
(8H, m, 4-CH2, 2,6-CH and PI1CH2CH2CH2); 2.15 (2H, d, 14.5 Hz, 2,6-CH); 2.56
(2H, t, 8 Hz, PhCH2CH2CH2); 3.93 (2H, s, CH2CI); 6.5 (1 H, br s, NH) and 7.1-7.4
ppm. (5H, m, Ph).
c) 4-{1-[{2-Chloroacetyl)amino]-3,3,5,5-tetramethylcycIohexyl}butanoic acid (22-2).
Prepared in 74% yield from amide 21-2 according to the procedure described in
Example 9a. Colorless solid with mp 140-141 °C.
1H-NMR (CDCb, TMS) δ: 0.91 (6H, s, 3,5-CHs); 1.15 (6H, s, 3,5-CHs); 0.9-1.8
(8H, m, 4-CH2, 2,6-CH, OCCH2CH2CH2); 2.17 (2H, d, 14.2 Hz, 2,6-CH); 2.33 (2H,
t, 7.2 Hz, OCCH2CH2CH2); 3.97 (2H, s, CH2CI) and 6.6 ppm. (1 H, br s, NH).
d) Ethyl 4-{1 -[{2-chloroacetyl)amino]-3,3,5,5-tetramethylcycIohexyl}butanoate
(23-2).
Prepared in 98% yield from acid 22-2 according to the procedure described in
Example 9b. A colorless oil.
1H-NMR (CDCb, TMS) δ: 0.91 (6H, s, 3,5-CHs); 1 .14 (6H, s, 3,5-CHs); 1 .25 (3H, t,
7 Hz, CH3CH2O): 0.9-1.8 (4H, m, 4-CH2, 2,6-CH, OCCH2CH2CH2); 2.18 (2H, d, 15
Hz, 2,6-CH); 2.26 (2H, t, 8.4 Hz, OCCH2CH2CH2); 3.95 (2H, s, CH2CI); 4.13 (2H,
q, 7 Hz, CH3CH2O) and 6.52 ppm. (1 H, br s, NH).
e) 8,8,10,10-Tetramethyl-1-azaspiro[5.5]undecan-2-one (24-2).
Prepared in 76% yield from ester 23-2 according to the procedure described in
Example 9c. Colorless solid with mp 126-128° C. 'H-NMR (CDCb, TMS) δ: 1 .01 (6H, s, 8,10- CHs); 1 .09 (6H, s, 8, 10-CHs); 1.19 and
1.30 (both 1 H, d, 14 Hz, 9-CH2); 1.39 and 1 .46 (both 2H, d, 14 Hz, 7, 1 1 -CH2);
1.63-1.90 (4H, m, 4,5-CH2); 2.33 (2H, t, 6 Hz, 3-CH2) and 5.8 ppm. (1 H, br s,
NH).
f) 8,8,10,10-Tetramethyl-1-azaspiro[5.5]undecane hydrochloride (3-2).
Prepared in 45% yield from spirolactam 24-2 according to the procedure described
in Example 9d. A colorless solid.
1H-NMR (CDCb, TMS) δ: 1 .01 (6H, s, 8,10-CH3); 1 .09 (6H, s, 8,10-CH3); 1 .0-2.1
(12H, m, 3,4,5,7,9,1 1-CH2); 3.1 (2H, br s, 2-CH2) and 9.1 ppm. (2H, br s, NH2 +).
Overall synthetic scheme and table for 6-azatricyclo[6.3.1 .01,6] dodecanes
(belonging to the structure of formula 2 of the Summary).
Scheme 4
Figure imgf000053_0001
Table 4
MRZ number number in synthetic R R1 R2 R3 R4 R5 Y n descripition 2047 2 -(CH2)4-, (m = 1 ) Me Me Me H CH 0
Example 12.
8,10,10-Trimethyl-6-azatricyclo[6.3.1.0 ,6]dodecane hydrochloride (2).
a) δ O O-Trimethyl-e-azatricyclotθ.S.I .O^^dodecan-δ-one (25).
Prepared in 20% yield from spirolactam 24-2 according to the procedure described
in Example 3b. An oil.
1H-NMR (CDCb, TMS) δ: 0.95 (3H, s, 10-CHs); 1.00 (3H, s, 10-CHs); 1.08 (3H,
s, 8-CHs); 1 .20 (1 H, d, 12 Hz) and 1.25-1.70 (5H, m, 9,1 1 ,12 CH2); 1.75-1 .90
(4H, m, 2,3-CH2); 2.25-2.40 (2H, m, 4-CH2); 3.14 and 3.43 ppm (both 1 H, d,
Figure imgf000054_0001
b) 8,10,10-Trimethyl-6-azatricyclo[6.3.1.01'6]dodecane hydrochloride (2).
Prepared in 36% yield from lactam 25 according to the procedure given in Example
9d. A colorless solid.
1H-NMR (CDCb, TMS) δ: 0.85-2.45 (12H, m, 2,3,4,9,1 1 ,12-CH2); 0.99 (3H, s, 10-
CHs); 1 .05 (3H, s, 10-CHs); 1 .19 (3H, s, 8-CH3); 3.12 (2H, m, 5-CH2); 3.20-3.75
(2H, m, 7-CH2) and 9.05 ppm. (1 H, br s, NH+). PHARMACEUTICAL COMPOSITIONS
The active ingredients of the invention, together with one or more conventional adjuvants, carriers, or diluents, may be placed into the form of pharmaceutical compositions and unit dosages thereof, and in such form may be employed as solids, such as coated or uncoated tablets or filled capsules, or liquids, such as solutions, suspensions, emulsions, elixirs, or capsules filled with the same, all for oral use; in the form of suppositories or capsules for rectal administration or in the form of sterile injectable solutions for parenteral (including intravenous or subcutaneous) use. Such pharmaceutical compositions and unit dosage forms thereof may comprise conventional or new ingredients in conventional or special proportions, with or without additional active compounds or principles, and such unit dosage forms may contain any suitable effective amount of the active ingredient commensurate with the intended daily dosage range to be employed. Tablets containing twenty (20) to one hundred (100) milligrams of active ingredient or, more broadly, ten (10) to two hundred fifty (250) milligrams per tablet, are accordingly suitable representative unit dosage forms.
METHOD OF TREATING
Due to their high degree of activity and their low toxicity, together presenting a most favorable therapeutic index, the active principles of the invention may be administered to a subject, e.g., a living animal (including a human) body, in need thereof, for the treatment, alleviation, or amelioration, palliation, or elimination of an indication or condition which is susceptible thereto, or representatively of an indication or condition set forth elsewhere in this application, preferably concurrently, simultaneously, or together with one or more pharmaceutically-acceptable excipients, carriers, or diluents, especially and preferably in the form of a pharmaceutical composition thereof, whether by oral, rectal, or parental (including intravenous and subcutaneous) or in some cases even topical route, in an effective amount. Suitable dosage ranges are 1-1000 milligrams daily, preferably 10-500 milligrams daily, and especially 50-500 milligrams daily, depending as usual upon the exact mode of administration, form in which administered, the indication toward which the administration is directed, the subject involved and the body weight of the subject involved, and the preference and experience of the physician or veterinarian in charge.
EXAMPLES OF REPRESENTATIVE PHARMACEUTICAL COMPOSITIONS
With the aid of commonly used solvents, auxiliary agents and carriers, the reaction products can be processed into tablets, coated tablets, capsules, drip solutions, suppositories, injection and infusion preparations, and the like and can be therapeutically applied by the oral, rectal, parenteral, and additional routes. Representative pharmaceutical compositions follow.
(a) Tablets suitable for oral administration which contain the active ingredient may be prepared by conventional tabletting techniques.
(b) For suppositories, any usual suppository base may be employed for incorporation thereinto by usual procedure of the active ingredient, such as a polyethyleneglycol which is a solid at normal room temperature but which melts at or about body temperature.
(c) For parental (including intravenous and subcutaneous) sterile solutions, the active ingredient together with conventional ingredients in usual amounts are employed, such as for example sodium chloride and double-distilled water q.s., according to conventional procedure, such as filtration, aseptic filling into ampoules or IV-drip bottles, and autoclaving for sterility.
Other suitable pharmaceutical compositions will be immediately apparent to one skilled in the art.
The following examples are again given by way of illustration only and are not to be construed as limiting. EXAMPLE 1
Tablet Formulation
A suitable formulation for a tablet containing 10 milligrams of active ingredient is as follows:
Mg.
Active Ingredient 10
Lactose 63
Microcrystalline Cellulose 21
Talcum 4
Magnesium stearate 1
Colloidal silicon dioxide 1
EXAMPLE 2 Tablet Formulation Another suitable formulation for a tablet containing 100 mg is as follows:
Mg.
Active Ingredient 100
Potato starch 20
Polyvinylpyrrolidone 10 Film coated and colored. The film coating material consists of:
Lactose 100
Microcryst. Cellulose 80
Gelatin 10
Polyvinylpyrrolidone, crosslinked 10
Talcum 10
Magnesium stearate 2
Colloidal silicon dioxide 3
Color pigments 5
EXAMPLE 3
Capsule Formulation
A suitable formulation for a capsule containing 50 milligrams of active ingredient is as follows:
Mg.
Active Ingredient 50
Corn starch 20
Dibasic calcium phosphate 50
Talcum 2
Colloidal silicon dioxide 2
filled in a gelatin capsule.
EXAMPLE 4
Solution for injection
A suitable formulation for an injectable solution containing one percent of active ingredient is as follows:
Active Ingredient mg 12 Sodium chloride mg 8 Sterile water to make ml 1
EXAMPLE 5
Liquid oral formulation
A suitable formulation for 1 liter of a liquid mixture containing 2 milligrams of active ingredient in one milliliter of the mixture is as follows:
G.
Active Ingredient 2
Saccharose 250
Glucose 300
Sorbitol 150
Orange flavor 10
Sunset yellow.
Purified water to make a total of 1000 ml.
EXAMPLE 6
Liquid oral formulation
Another suitable formulation for 1 liter of a liquid mixture containing 20 milligrams of active ingredient in one milliliter of the mixture is as follows:
G.
Active Ingredient 20.00
Tragacanth 7.00
Glycerol 50.00
Saccharose 400.00
Methylparaben 0.50
Propylparaben 0.05
Black currant-flavor 10.00
Soluble Red color 0.02
Purified water to make a total of 1000 ml.
EXAMPLE 7
Liquid oral formulation
Another suitable formulation for 1 liter of a liquid mixture containing 2 milligrams of active ingredient in one milliliter of the mixture is as follows:
Active Ingredient 2
Saccharose 400
Bitter orange peel tincture 20
Sweet orange peel tincture 15 Purified water to make a total of 1000 ml.
EXAMPLE 8 Aerosol formulation 180 g aerosol solution contain:
Active Ingredient 10 Oleic acid 5
Ethanol 81 Purified Water 9
Tetrafluoroethane 75
15 ml of the solution are filled into aluminum aerosol cans, capped with a dosing valve, purged with 3.0 bar. EXAMPLE 9
TDS formulation
100 g solution contain:
Active Ingredient 10.0 Ethanol 57.5
Propyleneglycol 7.5 Dimethylsulf oxide 5.0 Hydroxyethylcellulose 0.4 Purified water 19.6
1.8 ml of the solution are placed on a fleece covereti by an adhesive backing foil. The system is closed by a protective liner which will be removed before use.
EXAMPLE 10
Nanoparticle formulation
10 g of pdlybutylcyanoacrylate nanoparticles contain:
Active Ingredient 1.00
Poloxamer 0.10
Butylcyanoacrylate 8.75
Mannitol 0.10
Sodiumchloride 0.05
Polybutylcyanoacrylate nanoparticles are prepared by emulsion polymerization in a water/0.1 N HCI/ethanol mixture as polymerizsation medium. The nanoparticles in the suspension are finally lyophilized under vacuum.
PHARMACOLOGY - SUMMARY
The active principles of the present invention, and pharmaceutical compositions thereof and method of treating therewith, are characterized by unique advantageous and unpredictable properties, rendering the "subject matter as a whole", as claimed herein, unobvious. The compounds and pharmaceutical compositions thereof have exhibited, in standard accepted reliable test procedures, the following valuable properties and characteristics:
They are systemically-active, uncompetitive NMDA receptor antagonists with rapid blocking/unblocking kinetics and strong voltage dependency and are, accordingly, of utility in the treatment, elimination, palliation, alleviation, and amelioration of responsive conditions, by application or administration to the living animal host for the treatment of a wide range of CNS disorders which involve disturbances of glutamatergic transmission.
These compounds are also systemically-active, non-competitive 5HT3 and neuronal nicotinic receptor antagonists and are, accordingly, of utility in the treatment, elimination, palliation, alleviation, and amelioration of responsive conditions, by application or administration to the living animal host for the treatment of a wide range of CNS disorders which involve disturbances of serotonin or nicotinic transmission.
Methods
Receptor Binding Studies
Male Sprague-Dawley rats (200-250g) were decapitated and their brains were removed rapidly. The cortex was dissected and homogenized in 20 volumes of ice-cold 0.32 M sucrose using a glass-Teflon homogenizer. The homogenate was centrifuged at 1000xg for 10 min. The pellet was discarded and the supernatant centrifuged at 20,000xg for 20 min. The resulting pellet was re- suspended in 20 volumes of distilled water and centrifuged for 20 min at 8000xg. Then the supernatant and the buffy coat were centrifuged at 48,000xg for 20 min in the presence of 50 mM Tris-HCI, pH 8.0. The pellet was then re- suspended and centrifuged two to three more times at 48,000xg for 20 min in the presence of 50 mM Tris-HCI, pH 8.0. All centrifugation steps were carried out at 4°C. After resuspension in 5 volumes of 50 mM Tris-HCI, pH 8.0 the membrane suspension was frozen rapidly at -80°C.
On the day of assay the membranes were thawed and washed four times by
resuspension in 50 mM Tris-HCI, pH 8.0 and centrifugation at 48,000xg for 20
min. and finally re-suspended in 50 mM Tris-HCI, pH 7.4. The amount of protein
in the final membrane preparation (250-500 /g/ml) was determined according to
the method of Lowry et al. (1951 ). Incubations were started by adding [3H]-( + )-
MK-801 (23.9 Ci/mmol, 5nM, Dupont NEN) to vials with glγcine (10 μM),
glutamate (10 M), and 125-250 /g protein (total volume 0.5 ml) and various
concentrations of the agents tested (10 concentrations in duplicates). The
incubations were continued at room temperature for 120 min (equilibrium was
achieved under the conditions used). Non-specific binding was defined by the
addition of unlabeled ( + )-MK-801 (10 μM). Incubations were terminated using a
Millipore filter system. The samples were rinsed twice with 4 ml of ice cold
assay buffer over glass fibre filters (Schleicher & Schuell) under a constant
vacuum. Following separation and rinse the filters were placed into scintillation
liquid (5 ml; Ultima Gold) and radioactivity retained on the filters was determined with a conventional liquid scintillation counter (Hewlett Packard, Liquid
Scintillation Analyser). The Kd of [3H]-( + )-MK-801 of 4.6 nM was determined
by Scatchard analysis and used according to the Cheng Prussoff relationship to
calculate the affinity of displacers as Kd values. Most antagonists were tested in
3 to 7 separate experiments.
NMDA and Neuronal Nicotinic Receptor Subtype Expression in Xenopus Oocytes
Mature female Xenopus laevis were anaesthetized in 0.2% Tricaine on ice for
15 min prior to surgery. Oocytes were removed and incubated in 2 mg/ml
collagenase (type II) in Ca2+-free oocyte Ringer solution (82.5 mM NaCI, 2 mM
KCI, 2 mM MgCb, 5 mM HEPES, pH 7.5) for 30 min. at room temperature and
washed thoroughly with OR-2 (100 mM NaCI, 2 mM KCI, 1 mM MgCb, 2 mM
CaC , 5 mM HEPES, pH 7.5). The remaining follicle cell layer was removed
manually with fine forceps and the oocytes were kept in OR-2. The RNA was
dissolved in DEPC-treated, sterile distilled water. RNA for the NMDA NR1 a
subunit was mixed 1 : 1 with RNA for the NR2A subunit. Likewise neuronal
nicotinic α4 RNA was mixed 1 :1 with RNA for the β2 subunit. Fifty to 100
nanoliters of each RNA mixture were injected in the oocyte's cytoplasm using a
Nanoliter Injector (World Precision Instruments). The oocytes were incubated at
19°C in OR-2 for the following 3 to 6 days. The electrophysiological responses were obtained using the standard two-
electrode voltage-clamp method (GeneClamp 500 amplifier), 2-6 days after
injection. The electrodes had a resistance between 0.2 and 0.4 MΩ and were
filled with 3M KCI. Recordings were made in a custom made chamber with 2 to
3 second exchange times. The bath solution was prepared Ca2+-free, to avoid
Ca2+-induced CI" currents (100 mM NaCI, 2 mM KCI, 5 mM HEPES, 2 mM BaCb,
pH 7.35). NMDA receptors were activated by the manual co-application of 1
mM Glutamate and 10 μM Glycine for 30-40 sees every 2 to 3 mins to oocytes
clamped at -70mV. Neuronal nicotinic receptors were activated by application of
100 μM acetylcholine for 20-30 sees every 2 to 3 mins to oocytes clamped at -
70mV. After obtaining stable control responses, full concentration-response
curves with antagonists were obtained by preincubating 6-7 different
concentrations at log 3 intervals.
Only results from stable cells were accepted for inclusion in the final analysis i.e. showing at least 50% recovery of responses to NMDA following removal of the antagonist tested. Despite this, recovery from drug actions wasn't always 100% because of minor rundown or runup in some cells. When present, this was always compensated by basing the % antagonism at each concentration on both control and recovery and assuming a linear time course for this rundown. All antagonists were assessed at steady-state blockade with 6 to 7 concentrations on at least 4 cells. Equilibrium blockade was achieved within 1 to 3 agonist applications, depending on antagonist concentration.
Kinetic experiments were performed by applying various concentrations of unsaturated amino-alkyl-cyclohexanes (normally 5 in a log 3 dosing regime) for 10-20 seconds in the continuous presence of glutamate (100 μM and glycine 10 μM) for 90-180 seconds in Xenopus oocytes expressing NR1 a/2A receptors. The perfusion system used for these experiments was a modified oocyte carousel system which allows rapid wash in and wash out of agonist and antagonist with change times less than one second. Exponential fits were made using the program TIDA for windows and most responses were well fitted by a single exponential. This same system was used to access the voltage- dependency of blockade, but the bath solution contained flufenamic acid (100 μM) to block endogenous voltage-activated and Ca2+ activated CI" currents. Also, Ba2+ (2mM) was replaced by low concentrations of Ca2+ (0.2 mM). Following equilibrium blockade by higher concentrations of antagonist (normally around 10 times the ICso), five ramps were driven from -70 mV to + 30 mV over two seconds. Similar ramps were driven in bath solutions and for glutamate without antagonist, both before antagonist application and following recovery of responses. The leak currents in the absence of glutamate were substrated from the glutamate and glutamate plus antagonist curves. Voltage-dependency was then determined by comparing the glutamate and glutamate plus antagonist curves.
Patch Clamp for NMDA and Nicotine
Hippocampi were obtained from rat embryos (E20 to E21 ) and were then transferred to calcium and magnesium free Hank's buffered salt solution (Gibco) on ice. Cells were mechanically dissociated in 0.05% DNAase / 0.3% ovomucoid (Sigma) following an 8 minute pre-incubation with 0.66% trypsin /
0.1 % DNAase (Sigma). The dissociated cells were then centrifuged at 18xg for
10 minutes, re-suspended in minimum essential medium (Gibco) and plated at a density of 150,000 cells cm"2 onto poly-L-lysine (Sigma)-precoated plastic petri dishes (Falcon). The cells were nourished with NaHCOs/HEPES-buffered minimum essential medium supplemented with 5% fetal calf serum and 5% horse serum (Gibco) and incubated at 37C with 5%CO2 at 95% humidity. The medium was exchanged completely following inhibition of further glial mitosis with cytosine-D-arabinofuranoside (20M Sigma) after about 7 days in vitro. Thereafter the medium was exchanged partially twice weekly.
Patch clamp recordings were made from these neurones with polished glass electrodes (4-6 m) in the whole cell mode at room temperature (20-22C) with the aid of an EPC-7 amplifier (List). Test substances were applied by switching channels of a custom-made fast superfusion system with a common outflow (10-20 ms exchange times). The contents of the intracellular solution were as follows (mM): CsCI (120), TEACI (20), EGTA (10), MgCb(1 ),CaCl2(0.2), glucose (10), ATP(2), cAMP (0.25); pH was adjusted to 7.3 with CsOH or HCI. The extracellular solutions had the following basic composition (mM): NaCI (140), KCI (3), CaC (0.2), glucose (10), HEPES (10), sucrose (4.5), tetrodotoxin (TTX 3* 10"4). Glycine (1 M) was present in all solutions: a concentration sufficient to cause around 80-85% activation of glycineβ receptors. Only results from stable cells were accepted for inclusion in the final analysis, i.e., following recovery of responses to NMDA by at least 75% of their depression by the antagonists tested.
Patch Clamp for 5-HT3
N1 E-1 15 cells were purchased from the European collection of cell cultures (ECACC, Salisbury, UK) and stored at -80°C until further use. The cells were plated at a density of 100,000 cells cm"2 onto plastic Petri dishes (Falcon) and were nourished with NaHCOs/HEPES-buffered minimum essential medium supplemented (MEM) with 15% fetal calf serum (Gibco) and incubated at 37°C with 5%CO2 at 95% humidity. The medium was exchanged completely daily. Once every three days, cells were reseeded onto fresh Petri dishes following treatment with trypsin-EDTA (1 % in PBS), resuspension in MEM and centrifugation at 1000 rpm for four minutes. Patch clamp recordings at -70 mV were made from lifted cells, 2-3 days following seeding with polished glass electrodes (2-6MΩ) in the whole cell mode at room temperature (20-22°C) with an EPC-7 amplifier (List). The contents of the intracelluiar solution were as follows (mM): CsCI(130), HEPES (10), EGTA (10), MgCb (2), CaCb (2), K-ATP (2), Tris-GTP (0.2), D-glucose (10); pH was adjusted to 7.3 with CsOH or HCI. The extracellular solutions had the following basic composition (mM): NaCI (124), KCI (2.8), HEPES (10), pH 7.3 adjusted with NaOH or HCI.
After the whole-cell configuration was established, the cells were lifted from the glass substrate and serotonin (10μM), memantine and unsaturated amino- alkyl-cyclohexane derivatives were applied at various concentrations using a fast superfusion device. A piezo translator-driven double-barrelled application pipette was used to expose the lifted cell either to serotonin-free or serotonin-containing solution. A two second serotonin pulse was delivered every 6O seconds. The putative antagonists were dissolved in aqua-bidest and diluted with bath solution to the desired concentration. Only results from stable cells were accepted for inclusion in the final analysis, i.e., showing at least 50% recovery of responses to serotonin following removal of compounds. Despite this, recovery from drug actions wasn't always 100% because of rundown in some cells ( < = 10% over 10 minutes). When present, this was always compensated by basing the percent antagonism at each concentration on both control and recovery and assuming a linear time course for this rundown. All antagonists were assessed at steady-state blockade with 3 to 6 concentrations on at least five cells. Equilibrium blockade was achieved within 2 to 5 agonist applications, depending on antagonist concentration. In vivo
Anticonvulsive activity
NMR female mice (18-28 g) housed 5 per cage were used for the maximal electroshock (MES) and motor impairment tests. All animals were kept with water and food ad libitum under a 12 hour light-dark cycle (light on at 6 a.m.) and at a controlled temperature (20 + 0.5C). All experiments were performed between 10 a.m. and 5 p.m. Tested agents were injected 30 min. i.p. before the induction of convulsions if not stated otherwise (see below). All compounds were dissolved in 0.9% saline.
The MES test was performed together with tests for myorelaxant action (traction reflex) and motor coordination (rotarod). For the traction reflex test mice were placed with their forepaws on a horizontal rod and were required to place all 4 paws on the wire within 10 seconds. To test ataxia (motor coordination) mice were placed on an accelerating rotarod and were required to remain on the rod for 1 minute. Only mice not achieving the criteria in all three repetitions of each test were considered to exhibit myorelaxation or ataxia respectively. These tests were followed by MES (100 Hz, 0.5 second shock duration, 50 mA shock intensity, 0.9 ms impulse duration, Ugo Basile) applied through corneal electrodes. The presence of tonic convulsions was scored (tonic extension of hind paws with minimum angle to the body of 90). The aim was to obtain ED50S for all parameters scored (anticonvulsive activity and motor side effects) with use of the Litchfield Wilcoxon test for quantal dose responses. Division of the ED50 for side, effects (ataxia or myorelaxation) by the ED50 for antagonism of electroshock convulsions was used as a therapeutic index (TI).
Statistical analysis
IC50S in patch clamp and binding studies were calculated according to the four parameter logistic equation using the Grafit computer program (Erithacus Software, England). Ki value for binding studies were then determined according to Cheng and Prusoff. Binding values presented are means ± SEM of 3-5 determinations (each performed in duplicate).
4-7 doses of antagonists were tested in each of the in vivo tests (5-8 animals per dose) to allow calculation of graded EDsos according to probit analysis (Litchfield and Wilcoxon) with correction for 0% to 100% effects. EDsos are presented with 95% confidence limits (CI). Pearson product moment correlation analysis (Sigma Stat, Jandel Scientific) was used to compare in vitro potencies and in vivo anticonvulsant activity.
RESULTS
MRZ Numbers
MRZ numbers are used to represent chemical names. The MRZ numbers and their respective chemical names are shown in "MRZ LIST", and are cross- referenced in the Examples
MRZ LIST
MRZ Chemical Name
2/1013 8,8,10,10-Tetramethyl-1-azaspiro[5.5]undecane hydrochloride
2/1004 7,7,9,9-Tetramethyl-1-azaspiro[4.5]decane hydrochloride
2/1003 1,3,3,5,6-Perttamethyl-6-azabicyclo [3.2.1]octane hydrochloride
2/1010 1 ,3,3,5-Tetramethyl-6-azabicyclo [3.2.1]octane hydrochloride
2007 exo-3-Ethyl-1,5-dimethyl-6-azabicyclo[3.2.1 ]octane hydrochloride
2011 1 ,exo-3,5-Trimethyl-6-azabicyclo[3.2.1]octaπe hydrochloride
2022 5-Ethyl-1,3,3-trimethyl-6-azabicyclo[3.2.1]octane hydrochloride
2023 5-Ethyl-1,exo-3-dimethyl-6-azabicyclo[3.2.1]octane hydrochloride
1, exo-3,5-Trimethyl-exo,endo-7-phenyl-6-azabicyclo[3.2.1]octane
2028 hydrochloride
2029 1, exo-3,5, exo,encfo-7-Tetramethyl-6-azabicyclo[3.2.1]octane hydrochloride
2046 1 ,5,exo-7-Trimethyl-2-azabicyclo[3.3.1]nonane hydrochloride
2047 8,10,10-Trimethyl-6-azatricyclo[6.3.1.0 πdodecane hydrochloride Binding MK-801
All compounds displaced [3H]-( + )-MK-801 with Ki values between 1 and 83 μM (see Table 1 ).
Table 1
Figure imgf000073_0001
The results for representative compounds are reported in Figure 1 .
NMDA RECEPTOR SUBTYPE EXPRESSION IN XENOPUS OOCYTES.
NMDA receptor blockade by MRZ 2/1010 was determined by applying various concentrations (0.3 to 30 μM in a log 3 dosing regime) for 10 seconds in the continuous presence of glutamate (100 μM) and glycine 10 μM) at -70 mV for 100 seconds in Xenopus oocytes expressing NR1 a/2A receptors (Figure 2, left). The potency of MRZ 2/1010 (ICso = 0.76 μM, Hill 0.63) was determined by plotting percent blockade against antagonist concentration and then fitting the curve according to the logistic equation (Figure 2, right).
In vivo
Anti-Convulsive Activity
MES and Myorelaxant action results are presented in Table 2.
Table 2
-4
Figure imgf000075_0001
* * * * *
In conclusion, from the foregoing, it is apparent that the present invention provides novel, valuable, and unpredictable applications and uses of the compounds of the present invention, which compounds comprise the active principle according to the present invention, as well as novel pharmaceutical compositions thereof and methods of preparation thereof and of treating therewith, all possessed of the foregoing more specifically-enumerated characteristics and advantages.
The high order of activity of the active agent of the present invention and compositions thereof, as evidenced by the tests reported, is indicative of utility based on its valuable activity in human beings as well as in lower animals. Clinical evaluation in human beings has not been completed, however. It will be clearly understood that the distribution and marketing of any compound or composition falling within the scope of the present invention for use in human beings will of course have to be predicated upon prior approval by governmental agencies, such as the U.S. Federal Food and Drug Administration, which are responsible for and authorized to pass judgment on such questions.
Conclusions
The instant azabicyclic, azatricyclic and azaspirocyclic derivatives of aminocyclohexanes represent a novel class of systemically-active, uncompetitive NMDA receptor antagonists with rapid blocking/unblocking kinetics and strong voltage-dependency. In view of their moderate potency and associated rapid kinetics, they will be useful therapeutics in a wide range of CNS disorders which involve disturbances of glutamatergic transmission.
These compounds accordingly find application in the treatment of the following
disorders of a living animal body, especially a human. 1. Excitotoxicity such as ischaemia during stroke, trauma, hypoxia, hypoglycemia, glaucoma, and hepatic
encephalopathy. 2. Chronic neurodegenerative diseases such as Alzheimer's
disease, vascular dementia, Parkinson's disease, Huntington's disease, multiple
sclerosis, amyotrophic lateral sclerosis, AIDS-neurodegeneration,
olivopontocerebellar atrophy, Tourette's syndrome, motor neurone disease,
mitochondrial dysfunction, Korsakoff syndrome, Creutzfeldt-Jakob disease. 3.
Other disorders related to long term plastic changes in the central nervous
system selected from chronic pain, drug tolerance, dependence and addiction
(e.g., opioids, cocaine, benzodiazepines, nicotine, and alcohol). 4. Epilepsy,
tardive dyskinesia, schizophrenia, anxiety, depression, acute pain, spasticity,
and tinnitus.
Furthermore, it was found that these compounds are neuronal nicotinic receptor and 5HT3 receptor antagonists as well. The compounds of the invention thus find application in the treatment of disorders in a living animal body, especially a human, in both nicotinic and 5HT3 receptor mediated indications for both symptomatic and neuroprotective purposes (e.g. emesis, nicotine abuse, schizophrenia, cerebellar tremor, IBS, migraine, depressive disorders, cognitive disorders, Parkinson's disease treatment-related psychosis and appetite disorders).
In addition, as already stated, due to at least in part to their amine substituent, the compounds of the present invention are also effective in indications not related to the aforementioned mechanism of action, exhibiting immunomodulatory activity, antimalaria and antitrypanozomal potency, anti- Borna virus, anti-HSV and anti-Hepatitis C virus activity. The method-of-treating a living animal body with a compound of the invention, for the inhibition of progression or alleviation of the selected ailment therein, is as previously stated by any normally-accepted pharmaceutical route, employing the selected dosage which is effective in the alleviation of the particular ailment desired to be alleviated.
Use of the compounds of the present invention in the manufacture of a medicament for the treatment of a living animal for inhibition of progression or alleviation of selected ailments or conditions, particularly ailments or conditions susceptible to treatment with an NMDA receptor antagonist, neuronal nicotinic receptor antagonist, 5HT3 antagonist, or a compound exhibiting immunomodulatory activity, antimalaria and antitrypanosomal potency, anti- Borna virus, and anti-HSV and anti-Hepatitis C virus activity, is carried out in the usual manner comprising the step of admixing an effective amount of a compound of the invention with a pharmaceutically-acceptable diluent, excipient, or carrier, and the method-of-treating, pharmaceutical compositions, and use of a compound of the present invention in the manufacture of a medicament.
Representative pharmaceutical compositions prepared by admixing the active ingredient with a suitable pharmaceutically-acceptable excipient, diluent, or carrier, include tablets, capsules, solutions for injection, liquid oral formulations, aerosol formulations, TDS formulations, and nanoparticle formulations, thus to produce medicaments for oral, injectable, or dermal use, also in accord with the foregoing. References
1. R.L. Frank, H.K. Hall (1950) J. Am. Chem. Soc. 72: 1645-1648.
2. G.A. Hiegel, P. Burk. (1973) J. Org. Chem. 38:3637-3639.
3. N.F. Firrell, P.W. Hickmott. (1970) J. Chem. Soc. C:716-719.
4. G.H. Posner, L.L. Frye. (1984) Isr. J. Chem. 24:88-92.
5. G.L. Lemiere, T.A. van Osselaer, F.C. Anderweireldt. (1978) Bull. Soc. Chim. Belg. 87:771 -782.
6. H.O. House, J.M. Wilkins. (1976) J. Org. Chem. 4J.:(25) 4031 -4033.
7. A.R. Greenaway, W.B. Whalley. (1976) J. Chem. Soc. P.T. 1. : 1385- 1389.
8. S. Matsuzawa, Y. Horiguchi, E. Nakamura, I. Kuwajima. (1989) Tetrahedron 45: (2) 349-362.
9. H.O. House, W.F. Fischer. (1968) J. Org. Chem. 33:(3) 949-956.
10. Chiurdoglu, G., Maquestiau, A. (1954) Bull. Soc. Chim. Belg. 63: 357- 378.
1 1. Zaidlewicz, M., Uzarewicz A., Zacharewicz, W. (1964) Roczniki Chem. 38: 591 -597.
12. Crossley, A.W., Gilling, C. (1910) J. Chem. Soc. 2218.
13. Zaidlewicz, M., Uzarewicz, A. (1971 ) Roczniki Chem. 45: 1 187-1 194.
14. Lutz, E.T., van der Maas, J.H. (1981 ) Spectrochim. Acta, A. 38A: 283. 15. Lutz, E.T., van der Maas, J.H. (1981 ) Spectrochim. Acta, A. 37A: 129- 134.
16. Ramalingam K., Balasubramanian, M., Baliah, V. (1972) Indian J. Chem. 10: 366-369.
17. Hamlin, K.E., Freifelder, M. (1953) J. Am. Chem. Soc. 75: 369-373.
18. Hassner, A., Fibinger, R., Andisik, D. (1984) J. Org. Chem. 49: 4237- 4244.
19. W. Danysz, CG. Parsons, I. Bresink, G. Quack (1995) Drug News Perspect. 8:261 -277.
20. J.D. Leander, R.R. Lawson, P.L., Ornstein, D.M. Zimmerman (1988) Brain Res. 448: 1 1 5-120.
21. CG. Parsons, G. Quack, I. Bresink, L. Baran, E. Przegalinski, W. Kostowski, P. Krzascik, S. Hartmann, W. Danysz (1995). Neuropharmacology 34:1239-1258.
22. M.A. Rogawski (1993) Trends Pharmacol. Sci. 14:325-331 .
23. Booher J. and Sensenbrenner M. (1972). Neurobiology 2:97-105.
24. Dichter, M. (1987) Brain Research 149:279.

Claims

Claims
1. Compounds of formula (1 )
Figure imgf000081_0001
wherein R and R1 - R5 are each independently selected from Cι-6 alkyl groups, C2.β alkenyl groups, C2.6 alkynyl groups, C&.12 aryl-Cι-4 alkyl groups, optionally substituted Cβ-12 aryl groups and, in the case of R and R2 - R5, hydrogen atoms, with the proviso that at least one of R2 and R3 and at least one of R4 and R5 are other than hydrogen, or R and R1 together represent a C3-5 alkylene or alkenylene group, R2 - R5 being as defined above;
Y is CH; and
Z represents a valence bond or a methylene group or, in the case where R and R1 together represent said alkylene or alkenylene group, Z may additionally represent hydrogen atoms attached to Y and N respectively;
and optical isomers and pharmaceutically acceptable acid and base addition salts thereof.
2. The compounds of claim 1 being:
1,exo -3,5-trimethyl-6-azabicyclo[3.2.1]octane and its hydrochloride;
5-ethyl-1,exo-3-dimethyl-6-azabicyclo[3.2.1]octane and its hydrochloride; exo-3-ethyl-1 ,5-dimethyl-6-azabicyclo[3.2.1]octane and its hydrochloride;
1,3,3,5-tetramethyl-6-azabicyclo[3.2.1]octane and its hydrochloride; 1 ,3,3,5,6-pentamethyl-6-azabicyclo[3.2.1]octane and its hydrochloride;
5-ethyl-1 ,3,3-trimethyl-6-azabicyclo[3.2.1]octane and its hydrochloride;
1 ,exo-3,5,exo,endo-7-tetramethyl-6-azabicyclo[3.2.1]octane and its hydrochloride;
1 ,exo-3,5-trimethyl-exo,enc/o-7-phenyl-6-azabicyclo[3.2.1]octane and its hydrochloride;
1 ,5,exo-7-trimethyl-2-azabicyclo[3.3.1]nonane and its hydrochloride;
7,7,9,9-tetramethyl-1-azaspiro[4.5]decane and its hydrochloride;
8,8,10,10-tetramethyl-1-azaspiro[5.5]undecane and its hydrochloride; and
8,10,10-trimethyl-6-azatricyclo[6.3.1.01 ,6]dodecane and its hydrochloride.
3. A pharmaceutical composition comprising a compound as claimed in claim 1 or claim 2 in combination with one or more pharmaceutically acceptable diluents, excipients or carriers.
4. Use of a compound as defined in claim 1 but not subject to the proviso that at least one of R2 and R3 and at least one of R4 and R5 are other than hydrogen as or in the manufacture of an immunomodulatory, anti- malarial, anti-Borna virus, anti-Hepatitis C, anti-trypanosomal or anti-HSV medicament or a medicament for alleviation of a condition treatable by an NMDA, 5HT3 or neuronal nicotinic receptor antagonist.
5. Use as claimed in claim 4 wherein said condition treatable by an NMDA receptor antagonist is an excitotoxicity selected from ischaemia during stroke, trauma, hypoxia, hypoglycemia, glaucoma and hepatic encephalopathy; a chronic neurodegenerative disease selected from Alzheimer's disease, vascular dementia, Parkinson's disease, Huntington's disease, multiple sclerosis, amyotrophic lateral sclerosis, AIDS- neurodegeneration, olivopontocerebellar atrophy, Tourette's syndrome, motor neurone disease, mitochondrial dysfunction, Korsakoff syndrome and Creutzfeldt-Jakob disease; a disorder related to long term plastic changes in the central nervous system selected from chronic pain, drug tolerance, drug dependence and drug addiction; epilepsy; tardive dyskinesia; L-DOPA- induced dyskinesia; schizophrenia; anxiety; depression; acute pain; spasticity or tinnitus.
6. Use as claimed in claim 4 wherein said condition treatable by a 5HT3 receptor antagonist is selected from anxiety disorders, depressive disorders, Schizophrenia and treatment-related psychosis, drug and alcohol abuse disorders, cognitive disorders, Alzheimer's disease, Parkinson's disease, cerebellar tremor, migraine, appetite disorders, inflammatory bowel syndrome and emesis.
7. Use as claimed in claim 4 wherein said condition treatable by a neuronal nicotinic receptor antagonist is selected from Tourette's syndrome, anxiety disorders, Schizophrenia, drug abuse, nicotine abuse, coacine abuse, Morbus Huntington dyskinesia, L-DOPA-induces dyskinesia, attention deficit hyperactivity disorder, Alzheimer's disease, Parkinson's disease and pain.
8. A method of treating a living human or non-human animal subject for immunomodulatory, anti-malarial, anti-Borna virus, anti-Hepatitis C, antitrypanosomal or anti-HSV purposes or for alleviation of a condition treatable by an NMDA, 5HT3 or neuronal nicotinic receptor antagonist, comprising the step of administering to said subject an effective amount of a compound as defined in claim 1 but not subject to the proviso that at least one of R2 and R3 and at least one of R4 and R5 are other than hydrogen. 1 / 2
Figure imgf000084_0001
0.001 0.01 0.1 1 10 100
Concentration (μM)
MRZ 2/1010 MRZ 2/1013
Parameter Value Std. Error Parameter Value Std. Error
IC 50 6.1308 0.4393 IC 50 7.0540 0.6228 Slope factor 1.1338 0.0783 Slope factor 0.9762 0.0731
MRZ 2/1003 MRZ 2/1013
Parameter Value Std. Error Parameter Value Std. Error
IC 50 13.9625 1.6508 IC 50 27.5514 3.0482 Slope factor 1.0367 0.1136 Slope factor 0.9117 0.0835
FIG. 1 Xenopus Oocytes (NR1a/2A): 03 Sept 2001
Figure imgf000085_0001
FIG. 2
PCT/GB2003/001236 2002-03-21 2003-03-21 Azabicyclic, azatricyclic and azaspirocyclic derivatives of aminocyclohexane nmda, 5ht3, and neuronal nicotinic receptor antagoni sts WO2003080046A1 (en)

Priority Applications (10)

Application Number Priority Date Filing Date Title
CA002474637A CA2474637A1 (en) 2002-03-21 2003-03-21 Azabicyclic, azatricyclic and azaspirocyclic derivatives of aminocyclohexane nmda, 5ht3, and neuronal nicotinic receptor antagoni sts
AU2003216855A AU2003216855B2 (en) 2002-03-21 2003-03-21 Azabicyclic, azatricyclic and azaspirocyclic derivatives of aminocyclohexane NMDA, 5HT3, and neuronal nicotinic receptor antagonists
IL16404103A IL164041A0 (en) 2002-03-21 2003-03-21 Azabicyclic, azatricyclic and azaspirocyclic derivatives of aminocyclohexane nmda, 5ht3, and neuronal nicotinic receptor antagonist
EA200401230A EA007098B1 (en) 2002-03-21 2003-03-21 Azabicyclic, azatricyclic and azaspirocyclic derivatives of aminocyclohexane nmda, 5ht3, and neuronal nicotinic receptor antagonists
UA20041008550A UA77778C2 (en) 2002-03-21 2003-03-21 Azabicyclic, azatricyclic and azaspirocyclic derivatives of aminocyclohexanes as nmda, 5ht3, and nicotinic receptor antagonists
JP2003577874A JP4262606B2 (en) 2002-03-21 2003-03-21 Azabicyclic, azatricyclic and azaspirocyclic derivatives of aminocyclohexane as NMDA, 5HT3 and neuronal nicotinic receptor antagonists
KR1020047011982A KR100741257B1 (en) 2002-03-21 2003-03-21 Azabicyclic, azatricyclic and azaspirocyclic derivatives of aminocyclohexane as nmda, 5ht3, and neuronal nicotinic receptor antagonists
MXPA04007755A MXPA04007755A (en) 2002-03-21 2003-03-21 Azabicyclic, azatricyclic and azaspirocyclic derivatives of aminocyclohexane nmda, 5ht3, and neuronal nicotinic receptor antagoni sts.
EP03712394A EP1485086A1 (en) 2002-03-21 2003-03-21 Azabicyclic, azatricyclic and azaspirocyclic derivatives of aminocyclohexane as nmda, 5ht3, and neuronal nicotinic receptor antagonists
NO20044481A NO20044481L (en) 2002-03-21 2004-10-20 Azabicyclic, azatrocyclic and azaspirocyclic derivatives of amino cyclohexane NMDA, -5HT3 and neuronal nicotine receptor antagonists.

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US36638602P 2002-03-21 2002-03-21
US60/366,386 2002-03-21

Publications (1)

Publication Number Publication Date
WO2003080046A1 true WO2003080046A1 (en) 2003-10-02

Family

ID=28454794

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2003/001236 WO2003080046A1 (en) 2002-03-21 2003-03-21 Azabicyclic, azatricyclic and azaspirocyclic derivatives of aminocyclohexane nmda, 5ht3, and neuronal nicotinic receptor antagoni sts

Country Status (19)

Country Link
US (4) US7022729B2 (en)
EP (1) EP1485086A1 (en)
JP (1) JP4262606B2 (en)
KR (1) KR100741257B1 (en)
CN (1) CN1638762A (en)
AR (1) AR039008A1 (en)
AU (1) AU2003216855B2 (en)
CA (1) CA2474637A1 (en)
CO (1) CO5611104A2 (en)
EA (1) EA007098B1 (en)
GE (1) GEP20063954B (en)
IL (1) IL164041A0 (en)
MX (1) MXPA04007755A (en)
NO (1) NO20044481L (en)
PL (1) PL372701A1 (en)
TW (1) TW200306189A (en)
UA (1) UA77778C2 (en)
WO (1) WO2003080046A1 (en)
ZA (1) ZA200406940B (en)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011149862A1 (en) * 2010-05-27 2011-12-01 Targacept, Inc. Nicotinic receptor non-competitive antagonists modulators
WO2013067105A3 (en) * 2011-11-03 2013-07-11 Targacept, Inc. Nicotinic receptor non-competitive modulators
WO2013111799A1 (en) 2012-01-25 2013-08-01 国立大学法人東北大学 Brain function improver
US9713606B2 (en) 2013-03-14 2017-07-25 Boehringer Ingelheim International Gmbh Methods for treating pulmonary emphysema using substituted 2-Aza-bicyclo[2.2.1]heptane-3-carboxylic acid (benzyl-cyano-methyl)-amides inhibitors of cathepsin C
US9879026B2 (en) 2014-09-12 2018-01-30 Boehringer Ingelheim International Gmbh Substituted spirocycles

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1765287A2 (en) 2004-06-17 2007-03-28 Merz Pharma GmbH & Co. KGaA Immediate release formulations of memantine oral dosage forms
US20060205822A1 (en) * 2004-12-22 2006-09-14 Forest Laboratories, Inc. 1-Aminocyclohexane derivatives for the treatment of multiple sclerosis, emotional lability and pseudobulbar affect
EP2111858A1 (en) 2008-04-25 2009-10-28 EPFL Ecole Polytechnique Fédérale de Lausanne Novel treatment for alzheimer's disease
US20090275597A1 (en) * 2008-05-02 2009-11-05 Forest Laboratories Holdings Limited Methods of treating cns disorders

Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1153973A (en) * 1966-03-14 1969-06-04 Upjohn Co alpha,alpha-Diphenyl-beta-Methyl-1-Azaspiro[4,5]Decane (and [4,4]Nonane)-1-Propanols
GB1472334A (en) * 1973-07-14 1977-05-04 Tanabe Seiyaku Co 1-3-hydroxyphenyl-6-azabicyclo-3,2,1-octane derivatives and their use in pharmaceutical preparations
EP0018077A2 (en) * 1979-03-12 1980-10-29 Eli Lilly And Company Phenylmorphans, processes for their preparation and pharmaceutical compositions containing them
EP0072438A2 (en) * 1981-08-13 1983-02-23 BASF Aktiengesellschaft N-benzoyl-N'-phenyl urea, process for their preparation and their use in combating insects and spiders
JPS62297848A (en) * 1986-06-17 1987-12-25 Konica Corp Silver halide photographic sensitive material
WO1992012149A1 (en) * 1991-01-09 1992-07-23 Smithkline Beecham Plc Azabicydic and azatricydic derivatives, process and intermediates for their preparation and pharmaceutical compositions containing them
EP0578560A2 (en) * 1992-07-08 1994-01-12 Centre D'etudes Experimentales Et Cliniques De Physio-Biologie, De Pharmacologie Et D'eutonologie (Cepbepe) Amido-alcohol derivatives as psychotropic agents
WO1994008964A1 (en) * 1992-10-16 1994-04-28 Asahi Kasei Kogyo Kabushiki Kaisha N-phenethylazepine derivative and use thereof
WO1996006081A1 (en) * 1994-08-18 1996-02-29 Pfizer Inc. Neuroprotective 3-(piperidinyl-1)-chroman-4,7-diol and 1-(4-hydrophenyl)-2-(piperidinyl-1)-alkanol derivatives
US5936088A (en) * 1995-09-22 1999-08-10 Novo Nordisk A/S Substituted azacyclic or azabicyclic compounds with affinity and selectivity for nicotinic cholinergic receptors
WO2000032600A1 (en) * 1998-11-27 2000-06-08 Neurosearch A/S 8-azabicyclo[3.2.1]oct-2-ene and -octane derivatives
WO2001098253A2 (en) * 2000-06-20 2001-12-27 Merz Pharma Gmbh & Co. Kgaa 1-amino-alkylcyclohexanes as 5-ht3 and neuronal nicotinicreceptor antagonists

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3134952B2 (en) * 1991-09-18 2001-02-13 東洋紡績株式会社 Method for producing a twist-resistant polyester resin composition
US5900227A (en) * 1996-06-17 1999-05-04 Oklahoma Medical Research Foundation Multicyclic nitrone spin trapping compositions
US6951961B2 (en) * 2002-05-17 2005-10-04 Marina Nikolaevna Protopopova Methods of use and compositions for the diagnosis and treatment of infectious disease

Patent Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1153973A (en) * 1966-03-14 1969-06-04 Upjohn Co alpha,alpha-Diphenyl-beta-Methyl-1-Azaspiro[4,5]Decane (and [4,4]Nonane)-1-Propanols
GB1472334A (en) * 1973-07-14 1977-05-04 Tanabe Seiyaku Co 1-3-hydroxyphenyl-6-azabicyclo-3,2,1-octane derivatives and their use in pharmaceutical preparations
EP0018077A2 (en) * 1979-03-12 1980-10-29 Eli Lilly And Company Phenylmorphans, processes for their preparation and pharmaceutical compositions containing them
EP0072438A2 (en) * 1981-08-13 1983-02-23 BASF Aktiengesellschaft N-benzoyl-N'-phenyl urea, process for their preparation and their use in combating insects and spiders
JPS62297848A (en) * 1986-06-17 1987-12-25 Konica Corp Silver halide photographic sensitive material
WO1992012149A1 (en) * 1991-01-09 1992-07-23 Smithkline Beecham Plc Azabicydic and azatricydic derivatives, process and intermediates for their preparation and pharmaceutical compositions containing them
EP0578560A2 (en) * 1992-07-08 1994-01-12 Centre D'etudes Experimentales Et Cliniques De Physio-Biologie, De Pharmacologie Et D'eutonologie (Cepbepe) Amido-alcohol derivatives as psychotropic agents
WO1994008964A1 (en) * 1992-10-16 1994-04-28 Asahi Kasei Kogyo Kabushiki Kaisha N-phenethylazepine derivative and use thereof
WO1996006081A1 (en) * 1994-08-18 1996-02-29 Pfizer Inc. Neuroprotective 3-(piperidinyl-1)-chroman-4,7-diol and 1-(4-hydrophenyl)-2-(piperidinyl-1)-alkanol derivatives
US5936088A (en) * 1995-09-22 1999-08-10 Novo Nordisk A/S Substituted azacyclic or azabicyclic compounds with affinity and selectivity for nicotinic cholinergic receptors
WO2000032600A1 (en) * 1998-11-27 2000-06-08 Neurosearch A/S 8-azabicyclo[3.2.1]oct-2-ene and -octane derivatives
WO2001098253A2 (en) * 2000-06-20 2001-12-27 Merz Pharma Gmbh & Co. Kgaa 1-amino-alkylcyclohexanes as 5-ht3 and neuronal nicotinicreceptor antagonists

Non-Patent Citations (32)

* Cited by examiner, † Cited by third party
Title
"TimTec Natural compounds", 14 October 2002, TIMTEC, INC., NEWARK, DE, 19714-8941, USA *
A.R. GREENAWAY; W.B. WHALLEY, J. CHEM. SOC. P.T., vol. 1, 1976, pages 1385 - 1389
ACTA PHYTOPATHOLOGICA ACADEMIAE SCIENTIARUM HUNGARICAE (1981), 16(1-2), 249-58 *
BOOHER J.; SENSENBRENNER M., NEUROBIOLOGY, vol. 2, 1972, pages 97 - 105
BULL. SOC. CHIM. FR., vol. 2, 1987, pages 261 - 264 *
C.G. PARSONS ET AL., NEUROPHARMACOLOGY, vol. 34, 1995, pages 1239 - 1258
CHIURDOGLU, G.; MAQUESTIAU, A., BULL. SOC. CHIM. BELG., vol. 63, 1954, pages 357 - 378
CROSSLEY, A.W.; GILLING, C., J. CHEM. SOC., 1910, pages 2218
DATABASE CA [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; DARWISH, Y. M. ET AL: "Heterocyclic quaternary ammonium salts as plant growth retardants", XP002247395, retrieved from STN Database accession no. 97:2169 *
DATABASE CA [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; TAKAHASHI, NOBUYUKI ET AL: "Preparation of phenethylhexahydroazepine derivatives as agents with affinity for sigma receptor", XP002248386, retrieved from STN Database accession no. 121:205227 *
DATABASE CHEMCATS Chemical Abstracts Service, Columbus, Ohio, US; XP002247396 *
DATABASE CROSSFIRE BEILSTEIN [online] Beilstein Institut zur Förderung der Chemischen Wissenschaften, Frankfurt am Main, DE; XP002247394, Database accession no. 5577766(brn); 5586551(brn); 5615067(brn) *
DICHTER, M., BRAIN RESEARCH, vol. 149, 1987, pages 279
G.A. HIEGEL; P. BURK, J. ORG. CHEM., vol. 38, 1973, pages 3637 - 3639
G.H. POSNER; L.L. FRYE, ISR. J. CHEM., vol. 24, 1984, pages 88 - 92
G.L. LEMIERE; T.A. VAN OSSELAER; F.C. ANDERWEIRELDT, BULL. SOC. CHIM. BELG., vol. 87, 1978, pages 771 - 782
H.O. HOUSE; J.M. WILKINS, J. ORG. CHEM., vol. 41, no. 25, 1976, pages 4031 - 4033
H.O. HOUSE; W.F. FISCHER, J. ORG. CHEM., vol. 33, no. 3, 1968, pages 949 - 956
HAMLIN, K.E.; FREIFELDER, M., J. AM. CHEM. SOC., vol. 75, 1953, pages 369 - 373
HASSNER, A.; FIBINGER, R.; ANDISIK, D., J. ORG. CHEM., vol. 49, 1984, pages 4237 - 4244
J.D. LEANDER ET AL., BRAIN RES., vol. 448, 1988, pages 115 - 120
LUTZ, E.T.; VAN DER MAAS, J.H., SPECTROCHIM. ACTA, A., vol. 37A, 1981, pages 129 - 134
LUTZ, E.T.; VAN DER MAAS, J.H., SPECTROCHIM. ACTA, A., vol. 38A, 1981, pages 283
M.A. ROGAWSKI, TRENDS PHARMACOL. SCI., vol. 14, 1993, pages 325 - 331
N.F. FIRRELL; P.W. HICKMOTT, J. CHEM. SOC., vol. C, 1970, pages 716 - 719
PATENT ABSTRACTS OF JAPAN vol. 012, no. 192 (P - 712) 4 June 1988 (1988-06-04) *
R.L. FRANK; H.K. HALL, J. AM. CHEM. SOC., vol. 72, 1950, pages 1645 - 1648
RAMALINGAM K.; BALASUBRAMANIAN, M.; BALIAH, V., INDIAN J. CHEM., vol. 10, 1972, pages 366 - 369
S. MATSUZAWA ET AL., TETRAHEDRON, vol. 45, no. 2, 1989, pages 349 - 362
W. DANYSZ ET AL., DRUG NEWS PERSPECT., vol. 8, 1995, pages 261 - 277
ZAIDLEWICZ, M.; UZAREWICZ A.; ZACHAREWICZ, W., ROCZNIKI CHEM., vol. 38, 1964, pages 591 - 597
ZAIDLEWICZ, M.; UZAREWICZ, A., ROCZNIKI CHEM., vol. 45, 1971, pages 1187 - 1194

Cited By (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9532974B2 (en) 2010-05-27 2017-01-03 Targacept, Inc. Nicotinic receptor non-competitive antagonists
US10716770B2 (en) 2010-05-27 2020-07-21 Catalyst Biosciences, Inc. Nicotinic receptor non-competitive antagonists
CN104557568A (en) * 2010-05-27 2015-04-29 塔加西普特公司 Nicotinic receptor non-competitive antagonists
US10258582B2 (en) 2010-05-27 2019-04-16 Catalyst Biosciences, Inc. Nicotinic receptor non-competitive antagonists
WO2011149862A1 (en) * 2010-05-27 2011-12-01 Targacept, Inc. Nicotinic receptor non-competitive antagonists modulators
AU2011258553B2 (en) * 2010-05-27 2014-08-14 Targacept, Inc. Nicotinic receptor non-competitive antagonists
US8809397B2 (en) 2010-05-27 2014-08-19 Targacept, Inc. Nicotinic receptor non-competitive antagonists
CN102918021B (en) * 2010-05-27 2015-02-11 塔加西普特公司 Nicotinic receptor non-competitive antagonists
CN102918021A (en) * 2010-05-27 2013-02-06 塔加西普特公司 Nicotinic receptor non-competitive antagonists
WO2011149859A1 (en) * 2010-05-27 2011-12-01 Targacept, Inc. Nicotinic receptor non-competitive antagonists
RU2582339C2 (en) * 2010-05-27 2016-04-27 Таргасепт, Инк. Non-competitive nicotinic receptor antagonists
WO2013067105A3 (en) * 2011-11-03 2013-07-11 Targacept, Inc. Nicotinic receptor non-competitive modulators
US9173878B2 (en) 2012-01-25 2015-11-03 Tohoku University Brain function improving agent
WO2013111799A1 (en) 2012-01-25 2013-08-01 国立大学法人東北大学 Brain function improver
JPWO2013111799A1 (en) * 2012-01-25 2015-05-11 国立大学法人東北大学 Brain function improver
US9713606B2 (en) 2013-03-14 2017-07-25 Boehringer Ingelheim International Gmbh Methods for treating pulmonary emphysema using substituted 2-Aza-bicyclo[2.2.1]heptane-3-carboxylic acid (benzyl-cyano-methyl)-amides inhibitors of cathepsin C
US10238633B2 (en) 2013-03-14 2019-03-26 Boehringer Ingelheim International Gmbh Methods for treating pulmonary emphysema using substituted 2-Aza-bicyclo[2.2.1]heptane-3-carboxylic acid (benzyl-cyano-methyl)-amides inhibitors of Cathepsin C
US9879026B2 (en) 2014-09-12 2018-01-30 Boehringer Ingelheim International Gmbh Substituted spirocycles
USRE47636E1 (en) 2014-09-12 2019-10-08 Boehringer Ingelheim International Gmbh Substituted spirocycles

Also Published As

Publication number Publication date
US20040034055A1 (en) 2004-02-19
US7022729B2 (en) 2006-04-04
CN1638762A (en) 2005-07-13
KR20040091005A (en) 2004-10-27
CO5611104A2 (en) 2006-02-28
UA77778C2 (en) 2007-01-15
GEP20063954B (en) 2006-10-25
CA2474637A1 (en) 2003-10-02
IL164041A0 (en) 2005-12-18
AU2003216855A1 (en) 2003-10-08
US20060019982A1 (en) 2006-01-26
EP1485086A1 (en) 2004-12-15
EA200401230A1 (en) 2005-02-24
JP2005525385A (en) 2005-08-25
EA007098B1 (en) 2006-06-30
ZA200406940B (en) 2005-09-22
MXPA04007755A (en) 2004-10-15
AR039008A1 (en) 2005-02-02
AU2003216855B2 (en) 2005-08-18
NO20044481L (en) 2004-10-20
JP4262606B2 (en) 2009-05-13
US20070185151A1 (en) 2007-08-09
US20060019983A1 (en) 2006-01-26
KR100741257B1 (en) 2007-07-19
TW200306189A (en) 2003-11-16
PL372701A1 (en) 2005-07-25
US7238703B2 (en) 2007-07-03

Similar Documents

Publication Publication Date Title
US7238703B2 (en) Azabicyclic, azatricyclic and azaspirocyclic derivatives of aminocyclohexane NMDA, 5HT3, and neuronal nicotinic receptor antagonists
EP1009732B1 (en) 1-amino-alkylcyclohexane nmda receptor antagonists
US6071966A (en) 1-amino-alkylcyclohexane NMDA receptor antagonists
US20100298442A1 (en) 1-Amino-alkyl-cyclohexanes as 5-HT3 and neuronal nicotinic receptor antagonists
US6828462B2 (en) Unsaturated 1-amino-alkylcyclohexane NMDA, 5HT3, and neuronal nicotinic receptor antagonists
AU2002337389A1 (en) Unsaturated 1-amino-alkylcyclohexane NMDA,5HT3 and neuronal nicotinic receptor antagonists
AU2001281861A1 (en) 1-amino-alkylcyclohexanes as 5-HT3 and neuronal nicotinicreceptor antagonists
ZA200403456B (en) Unsaturated 1-amino-alkylcyclohexane NMDA, 5HT3 and neuronal nicotinic receptor antagonists.
MXPA99011993A (en) 1-amino-alkylcyclohexane nmda receptor antagonists

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2003216855

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2474637

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 1020047011982

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: PA/a/2004/007755

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 20038044900

Country of ref document: CN

WWE Wipo information: entry into national phase

Ref document number: 2003712394

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2004/06940

Country of ref document: ZA

Ref document number: 200406940

Country of ref document: ZA

WWE Wipo information: entry into national phase

Ref document number: 164041

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 1200400923

Country of ref document: VN

WWE Wipo information: entry into national phase

Ref document number: 2003577874

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 372701

Country of ref document: PL

WWE Wipo information: entry into national phase

Ref document number: 200401230

Country of ref document: EA

ENP Entry into the national phase

Ref country code: GE

Ref document number: GE P

WWE Wipo information: entry into national phase

Ref document number: 8454

Country of ref document: GE

WWP Wipo information: published in national office

Ref document number: 2003712394

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 2003216855

Country of ref document: AU